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ABSTRACT OF THE DISSERTATION 
The Role of FGF Signaling in the Regulation of Adult Murine Cardiomyocyte Contractility and Pathologic 
Hypertrophy 
By 
Sarah Nicole Cilvik 
Doctor of Philosophy in Biology & Biomedical Sciences 
Developmental Biology 
Washington University School of Medicine, 2014 
Professor David M. Ornitz, Chairperson 
 
Cardiovascular diseases (CVDs ) have been the leading cause of death in the United States for 
decades.  They cause significant strain on the heart, resulting in an ongoing remodeling process that 
initially maintains cardiac function, but ultimately becomes maladaptive.  The signaling pathways that 
drive cardiac remodeling are extremely complex and poorly understood, and therefore, a better 
understanding of the mechanisms involved in the development and progression of CVDs is essential in 
order to diagnose and treat these diseases more effectively.  Fibroblast growth factors (FGFs) and their 
receptors are part of a large family of highly conserved signaling molecules that have been implicated in 
postnatal cardiac remodeling.  FGF signaling increases following injury to the heart, and published 
studies demonstrate that FGF2 is cardioprotective following cardiac stress or injury. Despite the 
importance of FGF2 following injury, mice that lack or overexpress FGF2 develop normally and do not 
have any cardiac phenotype under homeostatic conditions. It is currently unknown how FGF signaling is 
regulated in the adult heart and why effects of FGF2 are only observed following injury.  As a result, it 
was the goal of my thesis research to gain a better understanding of the role of FGF signaling in adult 
cardiac remodeling.  I hypothesized that FGF signaling may be repressed in the adult heart under 
homeostatic conditions and becomes reactivated following injury.  I utilized a doxycycline-inducible, 
cardiomyocyte-specific, constitutively-active FGF receptor (caFGFR1) mouse model to test whether the 
cardiomyocyte has the capacity to respond to a cell autonomous FGF signal.  Induction of this transgene 
led to immediate changes in cardiac contractility and the eventual development of hypertrophic 
xii 
 
cardiomyopathy (HCM) without progression to heart failure or premature death. Induction of caFGFR1 
appears to increase the calcium sensitivity and decrease relaxation of the sarcomere through 
dephosphorylation of troponin I, and also by potentially increasing cytosolic calcium, mechanisms 
implicated in classic HCM models.  Our doxycycline-inducible cardiomyocyte-specific caFGFR1 mouse 
provides a unique model of HCM that can be utilized to further characterize pathways that lead to 
phenotype development, as well as prevention or reversal.
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Chapter 1 
Introduction: FGF Signaling in the Heart and Relevance to Postnatal Cardiac Remodeling 
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A. Significance – The burden of cardiovascular disease in the United States 
 An estimated 82 million American adults have at least one type of cardiovascular disease, such 
as hypertension, myocardial infarction (MI), stroke, heart failure, and congenital cardiac defects.  One out 
of every three deaths in the United States can be attributed to CVD, with an average of one American 
dying every 39 seconds [1].  CVD claims more lives than cancer, chronic lower respiratory disease and 
accidents combined, making it the leading cause of death in the United States in all but one year since 
1900 [1].  Its total costs (direct and indirect) were estimated to be close to $500 billion in 2012, accounting 
for 16% of total health expenditures, more than any other disease [1].  The American Heart Association 
(AHA) predicts that more than 40% of Americans will have some form of CVD by the year 2030, with total 
costs increasing to more than $1.1 trillion [1].  As such, CVD represents a tremendous and continually 
increasing physical and financial burden to both Americans and the health care system.  Therefore, a 
complete understanding of the mechanisms involved in the development and progression of CVD is 
essential in order to diagnose and treat these diseases more effectively, thus decreasing their morbidity 
and mortality. 
 
B. Cardiovascular Remodeling 
Cardiovascular diseases cause significant strain on the heart.  For example, hypertension results 
in a pressure overload that the heart must overcome to effectively pump blood out of the ventricles, while 
myocardial infarction results in muscle death, leading to an increased workload for surviving muscle. In 
any event, the heart responds to such stress or injury by altering its myocardial structure and function, 
often through reactivation of developmental signaling pathways.  Given the limited proliferative capacity of 
adult cardiomyocytes, the adult heart must rely on hypertrophy of existing myocytes in order to increase 
its size, which initially normalizes wall stress and maintains cardiac function.  However, this pathological 
hypertrophy is characterized by predominantly increased myocyte width, fibrosis, and decreased 
ventricular chamber volume, and progressive remodeling inevitably leads to contractile dysfunction, 
ventricular dilatation, and heart failure [2-4].  In addition to pathological hypertrophy induced by an 
external cardiac stressor such as hypertension (secondary pathological hypertrophy), there is a primary 
myocardial disorder, hypertrophic cardiomyopathy (HCM), that is most often caused by mutations in 
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sarcomeric proteins.  Like secondary hypertrophy, HCM is also pathological and characterized by 
increased myocyte width and fibrosis.  However, what distinguishes HCM from other pathological 
hypertrophy is the presence of sarcomere disorganization and cardiomyocyte disarray.  Additionally, the 
majority of patients with this type of primary pathological hypertrophy have maintained or even enhanced 
systolic function; only in rare cases does HCM progress to heart failure [5, 6].   
In addition to primary and secondary pathological hypertrophy, there is a more beneficial 
(physiological) hypertrophy that allows the heart to increase in size in response to postnatal development 
(to adapt to the increasing size of the animal), as well as pregnancy or exercise (to adapt to increased 
workload demands).  Physiological hypertrophy is characterized by a predominant increase in myocyte 
length, absence of fibrosis, maintenance of chamber dimension, and normal or enhanced cardiac function 
[2, 3, 7, 8].  Many studies have attempted to elucidate mechanisms that result in hypertrophy, but this 
process is extremely complex and remains poorly understood, particularly with regard to mechanisms that 
distinguish the advantageous physiological hypertrophy from the detrimental pathological hypertrophy.  
Evidence has shown that developmental pathways and re-expression of fetal genes are involved in 
regulating postnatal cardiac growth [9-11], and thus it is essential to understand the normal 
developmental pathways and how they can be reactivated and reused for growth of adult tissues in order 
to manipulate remodeling mechanisms in a beneficial way.  As will be discussed below, fibroblast growth 
factor signaling is one such pathway that is crucial to various aspects of cardiac development, thus 
making it an excellent candidate for modulation of cardiac growth and physiology during the adult period. 
 
C. Fibroblast Growth Factor Family 
Fibroblast growth factors (FGFs) and their receptors are part of a large family of signaling 
molecules that are highly conserved and found in organisms ranging from C. elegans to humans [12-14].  
This diverse family of polypeptide growth factors is vital during embryogenesis, controlling cell 
proliferation and migration, as well as mesoderm formation, neural induction, anterior-posterior patterning, 
and endoderm formation.  In the adult, FGFs play an important role in the nervous system, in tissue 
healing and wound repair, and in tumor angiogenesis [15, 16].  These biological responses are mediated 
by the binding of FGFs to one of four distinct FGF receptor (FGFR) tyrosine kinases.  Regulation of 
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binding affinity and ligand specificity is achieved by the binding of FGFs to heparin sulfate proteoglycans 
(HSPG) in the extracellular matrix, as well as by alternative mRNA splicing of FGFRs [15, 16].  This 
splicing is tissue-specific, producing epithelial forms (b splice variants) and mesenchymal forms (c splice 
variants) [17-20].  Binding of FGFs and HSPGs together to the receptor causes receptor dimerization and 
tyrosine kinase autophosphorylation of the intracellular domain.  Downstream FGF signal transduction 
can proceed via three main pathways—Ras/MAP kinase pathway, phospholipase Cγ (PLCγ)/Ca
2+
 
pathway, or PI3 kinase/Akt pathway—but activation of p38 MAPK, Jun N-terminal kinase (JNK), signal 
transducer and activator of transcription (STAT), and ribosomal protein S6 kinase 2 (RSK2) pathways can 
occur in certain cellular contexts (Figure 1.1) [15, 16, 21]. 
 Most of the 22 FGFs identified in mammals are secreted proteins, and their expression is highly 
variable.  Some are ubiquitously expressed throughout life, such as FGF1 and FGF2, while other FGFs 
are restricted to a particular cell type and/or particular developmental stage [22].  Of the 22 FGFs, several 
are expressed in the heart and have been shown to be important for both cardiac development and 
response to injury.  However, the precise roles for FGF signaling during cardiovascular development, 
homeostasis, and response to injury, as well as how the FGF network interacts with other signaling 
pathways active in the heart, are only beginning to be elucidated. 
 
D. Fibroblast Growth Factor Signaling in Heart Development 
FGF ligands in the embryonic heart. Of the 22 known Fgf genes in mammals, several are 
expressed in the developing heart.  The expression of both FGF ligands and receptors in cardiac and 
vascular mesoderm, in mesothelium, and in endoderm suggests an important role for these molecules in 
development.  The first FGFs discovered in heart tissue were FGF1 and FGF2 (or acidic and basic FGF, 
respectively).  Both ligands are expressed ubiquitously throughout development and adulthood, and, 
unlike other FGFs, they are not efficiently secreted [23].  Both Fgf1 and Fgf2 are expressed in 
cardiomyocytes and vascular endothelial cells and are capable of stimulating cardiomyocyte and 
endothelial cell proliferation [24-30].  Surprisingly, however, knockout of Fgf1, Fgf2, or both has little 
developmental consequence in the heart [23, 31, 32]. 
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Fgf9, Fgf16, and Fgf20 are closely related ligands that are expressed in the developing heart, 
specifically in the epicardium and endocardium during midgestation development [33-36].  My lab has 
shown previously that FGF9 is necessary for cardiomyocyte proliferation during embryonic heart 
development, as FGF9-knockout mice have smaller hearts than wild-type mice [36].  Studies examining 
FGF16 have indicated that this growth factor is expressed in and released from cardiomyocytes in both 
the embryonic and postnatal heart, and that knockout of FGF16 also results in significantly smaller hearts 
compared to WT mice, again as a result of decreased cardiomyocyte proliferation during embryonic 
development [37-39]. 
Several other FGFs are expressed in the second heart field (SHF), a population of cardiac 
progenitor cells in the pharyngeal mesoderm.  These ligands have been shown to be important in the 
development cardiac outflow tract, right ventricle, and atrial myocardium [40].  FGF8 is the primary ligand 
involved in SHF development; it is expressed in a subset of primary heart field cells, throughout the SHF 
mesoderm, and in pharyngeal endoderm, where it has been shown to be chemotactic and chemokinetic 
for cardiac neural crest cells [40-42].  It is involved in left-right axis formation and normal looping of the 
heart tube [43], in addition to being required for expansion of the primary heart tube and for normal 
outflow tract development.  Fgf8 hypomorphs have disrupted right ventricle development and a spectrum 
of outflow tract defects, from hypoplastic outflow tracts to disrupted ventriculoarterial alignments (double 
outlet left ventricle, transposition of the great vessels) or failed septation of the outflow tract (persistent 
truncus arteriosus) [40, 41, 44-47].  
Other FGF ligands, such as FGF10, cooperate with FGF8 in the SHF.  Fgf10 is expressed in the 
SHF, and loss of function of FGF10 in combination with conditional loss of FGF8 in pharyngeal 
mesoderm leads to more severe outflow tract alignment defects than seen in Fgf8 mutants alone [48-51].  
In addition, Fgf10 is expressed in the developing myocardium, and our lab has shown recently that 
knockout of Fgf10 leads to a thin-walled myocardium due to impaired migration of epicardial-derived 
fibroblasts and decreased cardiomyocyte proliferation [52]. 
FGF3 has also shown redundancy with FGF10 during early heart development.  Fgf3 is 
expressed in the lateral pharyngeal ectoderm and in the pharyngeal pouch, adjacent to Fgf10 expression 
in the pharyngeal mesoderm [53].  Compound knockouts of Fgf3 and Fgf10 have a spectrum of defects 
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affecting the outflow tract, ventricular septum, atrioventricular cushions, ventricular myocardium, dorsal 
mesenchymal protrusion, pulmonary arteries, epicardium, and fourth pharyngeal arch artery, suggesting 
that these two ligands are essential for the normal developmental coordination of cardiovascular 
progenitors from the SHF and cardiac neural crest [53]. 
Fgf15 is another ligand expressed in the developing pharyngeal arches and is required for normal 
outflow tract development, as well as for ventricular septation [54, 55].  Loss of this protein results in 
alignment defects of the great vessels, overriding aorta or double outlet right ventricle, and ventricular 
septal defects, presumably through defective neural crest cell movement and accumulation during outflow 
tract remodeling [54, 55].  These findings may be applicable to FGF19, the human homolog of Fgf15 [54]. 
Finally, Fgf6, Fgf7, Fgf17, and Fgf18 are also expressed in the developing heart, but little is 
known regarding their functions [56-62]. 
FGF receptors in heart development.  FGFs bind to one of four distinct FGF receptor (FGFR) 
tyrosine kinases, which undergo tissue-specific alternative mRNA splicing, producing epithelial forms (b 
splice variants) and mesenchymal forms (c splice variants) [17-20].  Fgfrs are widely expressed 
throughout development, and several Fgfrs are expressed in the developing heart, as identified by in situ 
hybridization and immunohistochemical studies [63-65].  Fgfr1 is the primary Fgfr expressed in heart 
muscle. Consistent with the known tissue-specific alternative splicing of Fgfrs, the mesenchymal splice 
form (Fgfr1c) was the major form identified in both the embryonic and adult heart [66, 67]. In previous 
work, my lab has demonstrated myocardial expression of Fgfr1 and Fgfr2 during midgestation heart 
development, but was not able to detect expression of Fgfr3 or Fgfr4 in the embryonic heart [36]. 
 In differing mouse models, all Fgfrs have been knocked out, but the phenotypes have not been 
informative with respect to heart development, either due to embryonic lethality prior to critical stages of 
heart development (Fgfr1 and Fgfr2) or to lack of an obvious cardiac phenotype in viable mice (Fgfr3 and 
Fgfr4) [68-72].  Chimera analysis, using embryonic stem cells lacking functional Fgfr1, showed a 
deficiency in the ability of Fgfr1
-/-
 cells to contribute to the extra-embryonic, cephalic, heart, axial and 
paraxial mesoderm, and endoderm at E9.5, or to differentiate into cardiomyocytes in vitro [73, 74].  This 
suggested that FGFR1 may be required for neural crest cell migration, early patterning of the precardiac 
mesoderm, or cardiomyocyte differentiation.  Our lab previously investigated the necessity for 
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cardiomyocyte FGF receptors through creation of a myocardial-specific knockout of both Fgfr1 and Fgfr2 
(Mlc2v-Cre DCKO), and found a significant decrease in embryonic cardiomyocyte proliferation [36].  
Additionally, recent evidence suggests that FGF receptors 1 and 2 are required in the SHF mesoderm 
(and not in endothelium or cardiac neural crest cells) for proper formation, alignment, and septation of the 
outflow tract [75]. 
Fgfr2 null embryos are not viable due to a placental defect [68], but targeted knockout of the b 
splice form of FGFR2 has yielded more useful information regarding the role of this receptor in heart 
development.  While loss of the epithelial Fgfr2b results in severe defects incompatible with life beyond 
birth (lack of limbs, lungs, and anterior pituitary), closer analysis during embryonic development revealed 
that these mice have ventricular septal defects associated with overriding aorta or double outlet right 
ventricle, in addition to ventricular anomalies (thin myocardial wall, abnormal trabeculation [49, 76].  The 
ventricular defects were found to be the result of impaired migration of epicardial-derived fibroblasts and 
decreased cardiomyocyte proliferation, similar to the cardiac phenotype of Fgf10 null mice [52].  This 
phenotype was recapitulated with an epicardial knockout of both Fgfr1 and Fgfr2, suggesting that these 
receptors function redundantly in the epicardium to regulate fibroblast migration and myocardial growth 
[52]. 
 
E. Fibroblast Growth Factor Signaling in the Postnatal Heart 
 Clearly, a great deal is known about the expression, activity and function of FGF signaling during 
heart development, but there is much less knowledge about the expression and function of FGF ligands 
and receptors in the postnatal heart.  FGF1 and FGF2 are the most extensively studied FGF ligands in 
the adult heart.  As mentioned previously, both ligands are expressed ubiquitously throughout 
development and adulthood, but single knockout of either ligand or double knockout of both FGF1 and 
FGF2 has little or no consequence in the mouse heart [23, 31, 32].  Additionally, despite the ability of 
FGF1 and FGF2 to stimulate cardiomyocyte proliferation in vitro, cardiac-specific FGF1 or FGF2 
transgenic mice, have normal postnatal development with no development of cardiac hypertrophy [26, 29, 
30, 77, 78].  Cardiac-specific FGF1 overexpression, however, results in an altered vascular pattern and 
enhanced coronary flow [78].   
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Studies have strongly implicated FGF2 in the development of pathological hypertrophy in 
response to pressure overload in the adult heart.  Addition of FGF2 to cultured neonatal rat 
cardiomyocytes leads to repression of adult cardiac genes and induction of embryonic genes, an 
expression profile characteristic of pressure overload-induced hypertrophy [10, 79-82].   Furthermore, the 
hypertrophy exhibited by paced adult rat cardiomyocytes is prevented by an anti-FGF2 antibody [83]. 
Thus, it is not surprising that mice lacking FGF2 develop significantly less hypertrophy than wild-type mice 
after being subjected to pressure overload by transverse aortic constriction (TAC) [31].  Many other 
studies have demonstrated that FGF2 is both necessary and sufficient for the development of 
pathological hypertrophy.  Systemic administration of FGF2 following acute myocardial infarction in rats 
induces significant hypertrophy in non-infarcted myocardium [84].  Additionally, knockout of Fgf2 
prevented  the development isoproterenol- and angiotensin II-induced pathological hypertrophy in the 
adult heart, while FGF2 transgenic hearts showed an exacerbated hypertrophic response to -adrenergic 
stimulation, an effect mediated by signaling through ERK1/2 [85, 86]. 
Furthermore, studies have indicated that both FGF1 and FGF2 are protective against other types 
of injury to the adult heart, presumably through induction of angiogenesis.  FGF1 is a potent angiogenic 
factor and has been shown in a variety of in vivo and ex vivo models of ischemia to improve collateral 
flow and LV function by induction of new vessel formation and reduction of apoptosis, effects mediated 
through induction of ERK1/2, protein kinase C, and inducible nitric oxide synthase (iNOS) [87-93].  
Delivery of FGF2 to the heart has also been shown to enhance new vessel growth and collateral blood 
flow following myocardial ischemia or other injury [94-96].  Meanwhile, genetic models have 
demonstrated that FGF2-deficient mouse hearts have increased infarct sizes and reduced recovery of 
function following ex vivo ischemia-reperfusion injury compared to WT hearts, while cardiac-specific 
FGF2-overexpressing hearts exhibit decreased infarct sizes and increased recovery of function compared 
to WT [77].  Similarly, following induction of myocardial infarction (MI) by ligation of the left anterior 
descending (LAD) artery, Fgf2-knockout hearts have reduced fibroblast proliferation and collagen 
deposition, decreased endothelial proliferation and vascular density, decreased cardiomyocyte 
hypertrophy, increased final infarct size (infarct expansion), and impaired cardiac function compared to 
WT mice.  In contrast, FGF2-overexpressing hearts show increased fibroblast proliferation and collagen 
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deposition, enhanced cardiomyocyte hypertrophy, and preserved function, as previously seen in the ex 
vivo work-performing heart model of ischemia-reperfusion [97].     
In recent years, knowledge regarding the role of other FGF ligands in the adult heart has 
expanded significantly.  Fgf9 is expressed at low levels in the adult heart [98], and one study analyzing 
gene expression before and after implantation of a left ventricular assist device (LVAD) found that Fgf9 
expression is significantly decreased after mechanical unloading of the ventricle, suggesting that 
expression was increased in the failing heart [99].  The role of FGF9 in the postnatal heart was recently 
investigated utilizing a mouse model with inducible cardiomyocyte-specific expression of FGF9 [100].  
These mice develop enhanced myocardial microvascular density and cardiac hypertrophy (increased LV 
wall thickness without increased cavity diameter) with normal diastolic and systolic function and no 
changes in the expression of pathological markers (Anp, Bnp, MHC).  Additionally, when subjected to 
myocardial infarction (MI), these mice develop increased hypertrophy, greater capillary density, 
decreased interstitial fibrosis, and attenuated induction of pathological markers compared to control mice.  
Adenoviral gene transfer of FGF9 by injection into the LV cavity immediately after ligation of the left 
anterior descending artery resulted in increased capillary density and LV wall thickness, improved systolic 
function, and reduction of post-MI mortality compared to control mice [100].  These findings suggest that 
FGF9 may be more beneficial and cardioprotective to the adult heart than FGF2, since induction of FGF9 
did not result in increased interstitial fibrosis or upregulation of pathological markers. 
In addition to FGF9, studies are beginning to shed some light on the role of the closely related 
FGF16.  Unlike Fgf9, which decreases expression postnatally, Fgf16 expression increases markedly 
during the early neonatal period and persists into adulthood [39].  In contrast to the postnatal effects of 
FGF9 and the role of FGF16 in regulating embryonic cardiac growth [37, 38], this ligand appears to block 
the FGF2-mediated growth and proliferation of cultured neonatal cardiomyocytes, through modulation of 
protein kinase C (PKC) activation [39].  However, no studies have investigated the in vivo functions of 
FGF16 in the postnatal heart. 
Atypical FGFs and the adult heart.  Most members of the FGF family signal over short 
distances, in an autocrine or paracrine fashion.  However, there are a few FGFs that behave differently 
and are also significant in postnatal cardiac pathophysiology.  FGF23, the most recently discovered 
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ligand, is a bone-derived endocrine hormone that regulates serum phosphate levels.  Like other FGF 
ligands discussed above, systemic FGF23 expression has been found to lead to pathological cardiac 
hypertrophy [101].   
Other atypical FGFs are the intracellular FGFs, or fibroblast growth factor homologous factors 
(FHFs).  FGFs 11-14 lack signal sequences, are not secreted, and do not bind to FGF receptors.  Instead, 
these four FGFs are intracellular proteins that bind to and modulate the activity of voltage-gated sodium 
channels.  All of these FGFs are highly expressed in the developing heart [102], but FGF13 is the most 
abundant in the adult mouse heart [103, 104] and directly binds to the principal cardiac voltage-gated 
sodium channel, Nav1.5 [104].  Knockdown of FGF13 reduces sodium current and surface Nav1.5 
expression, without affecting total Nav1.5 protein or gene expression, resulting in delayed channel 
recovery from inactivation and slowed conduction velocity [104].  These findings suggest that not-yet-
recognized loss-of-function mutations in FGF13 may lead to cardiac arrhythmias, such as Long QT 
syndrome or Brugada syndrome [105]. 
FGF receptors in the adult heart.  There is conflicting evidence regarding both the expression 
and function of FGF receptors in the adult heart.  One study utilizing normal adult human heart samples 
found expression of all four FGFRs using immunohistochemistry [106].  FGFR1 was expressed at high 
levels in cardiomyocytes, along with FGFR2 and FGFR4.  Meanwhile, coronary arteries, veins, and 
microvessels showed the highest expression of FGFR3 and lower levels of FGFR1 and FGFR2 [106].  In 
contrast, a study in rats utilizing quantitative in vitro autoradiography to image FGFRs that bind to a 
labeled FGF2 found very low levels of FGF receptor expression in the adult myocardium, with only the 
blood vessels showing a high density of receptors [107].  Yet another study demonstrated very low, but 
detectable, gene expression of Fgfr1 in isolated adult rat cardiomyocytes [108]. 
Several studies have investigated changes in Fgfr1 expression following hypertrophy or MI.  In a 
rat model of hypertrophy, Fgfr1 expression was upregulated in the heart one day following ligation of the 
abdominal aorta, but returned to basal levels at day six [109].  Meanwhile, in a rat MI model, Fgfr1 gene 
expression was decreased three days after ligation of the left anterior descending artery (LAD), but 
increased in the border zone and noninfarcted myocardium at day seven and peaked at day 14.  
Expression remained elevated in the border zone for six weeks [110].  In contrast, another study 
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examining FGFR expression (as measured utilizing quantitative in vitro autoradiography for FGF-2 
binding) following MI in rats found that expression started to increase at day three and remained elevated 
through the end of the study (day 14), although the earlier change in receptor expression in this study 
could reflect changes in the expression one or more of the other FGF receptors [107]. 
Limited functional studies have been performed to determine whether FGF receptors are 
necessary or sufficient for ventricular remodeling in the adult heart.  Intramyocardial injection of an 
adenoviral FGFR1 dominant negative signaling construct abrogated FGF signaling and resulted in an 
intermediate degree of cardioprotection in an ex vivo ischemia-reperfusion model [111].  In contrast, 
endothelium-specific overexpression of constitutively-active FGFR2 resulted in a significant 
cardioprotective effect following myocardial infarction (reduced infarct size) via promotion of enhanced 
angiogenesis, anti-apoptotic effects on vascular smooth muscles cells and cardiomyocytes, and autocrine 
production of FGF2 [112].  Additionally, inhibition of FGFR1 abrogated the cardioprotective effects seen in 
an FGF1-transgenic mouse model of ex vivo ischemia-reperfusion [90].   
These studies investigating FGF signaling in the adult heart provide useful insights for the 
potential roles of this developmental pathway in cardiac remodeling, but they also raise many questions.  
At present, only FGF2 is definitively both necessary and sufficient in vivo for cardiac remodeling following 
injury to the heart.  FGF2 is capable of stimulating cardiomyocyte proliferation and hypertrophy in vitro, 
raising that question of why there is no growth deficiency in FGF2-knockout hearts or increased cardiac 
growth in FGF2-transgenic hearts.  Additionally, many of the studies described above utilized transgenic 
models of ligand overexpression to demonstrate that FGF signaling is capable of inducing hypertrophy or 
other ventricular remodeling, but there is limited evidence regarding how expression of these ligands and 
receptors is altered following different cardiac stressors (exercise, pressure overload, MI, etc.) or whether 
these ligands are necessary to the remodeling process.   My investigation into changes in cardiac gene 
expression in the FGF pathway in response to different stimuli (MI, aortic constriction, angiotensin II, 
swimming, and a genetic model of physiologic hypertrophy) will be presented in chapter two.  
Furthermore, there is a general lack of evidence regarding the cellular targets of FGF signaling; studies 
utilizing conditional knockouts of FGF receptors as well as ligands that are required to truly determine the 
necessity of these factors during the ventricular remodeling process.  My preliminary studies investigating 
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the necessity for cardiomyocyte FGF receptors 1 and 2 for remodeling and cardiac function following MI 
will be presented in chapter two with a discussion of future loss of function studies in chapter five.  Finally, 
FGF2, FGF9, and FGF23 were all sufficient to induce hypertrophy in either the uninjured (FGF9, FGF23) 
or injured (FGF2, FGF9) heart, but it is unclear whether these effects are due to a direct effect on the 
cardiomyocyte in vivo, or an indirect effect mediated by another cell type (as was proposed for FGF9).  
Chapter three will focus on my studies utilizing a cardiomyocyte-specific inducible constitutively-active 
FGFR1 to investigate the cell autonomous effects of FGF signaling, and address the question as to 
whether adult cardiomyocytes are competent to respond to an activated FGF receptor. 
 
F. Implication of FGF-activated Signaling Pathways in Hypertrophy 
Thus far, the discussion has focused on the functional effects of FGF signaling in the developing 
and adult heart.  The more important discussion, however, is the downstream mechanisms through which 
FGFs exert their effects and the fact that many of these pathways are strongly implicated in the 
pathogenesis of ventricular remodeling, especially in the development of hypertrophy.  As summarized 
above, ligand-dependent receptor dimerization results in a conformational change in receptor structure 
that activates the tyrosine kinase domain (TKD), resulting in transphosphorylation of the TKD and 
intracellular tail.  These phosphorylated sites act as docking sites for adaptor proteins, such as FGFR 
substrate 2 (FRS2), which get directly phosphorylated by the receptor and drive activation of multiple 
signal transduction pathways, such Ras/MAP kinase, phospholipase Cγ (PLCγ) pathway, or PI3 
kinase/Akt pathway (Figure 1.1) [15, 16, 21].  As will be discussed below, past literature suggests a 
paradigm in which pathological and physiological hypertrophy are mediated by distinct signaling 
pathways, with activation of the Ras/MAPK/ERK pathway resulting in pathological hypertrophy and 
activation of the PI3K/Akt pathway resulting physiological hypertrophy.  However, recent reports present a 
much more complex picture in which the lines between beneficial physiological and maladaptive 
pathological hypertrophy are blurred. 
 “RASopathies” and Hypertrophic Cardiomyopathy.  Phosphorylation of FRS2 recruits the 
adaptor proteins son of sevenless (SOS) and growth factor receptor-bound 2 (GRB2), which activate the 
small GTPase RAS [21].  Additionally, FRS2 forms a complex with and phosphorylates the SH2 domain-
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containing protein tyrosine phosphatase, SHP2, which leads to the recruitment of an additional GRB2-
SOS1 complex by FRS2.  Recruitment of both GRB2 and SHP2 is essential for sustained activation of 
Ras [113].  RAS then activates RAF, which phosphorylates mitogen-activated protein kinase kinase 
(MEK), which finally phosphorylates and activates mitogen-activated protein kinases (MAPKs), most 
commonly ERK1/2.  (Figure 1.1) [21, 114]. 
 Recent evidence strongly suggests that aberrant RAS signaling can contribute to the 
pathogenesis of hypertrophic cardiomyopathy, which affects roughly one out of 500 adults and is the most 
common cardiovascular genetic disorder.  While the majority of cases (45-70%) can be attributed to one 
of many possible mutations in sarcomeric proteins [6], there are also some syndromic diseases (the 
“RASopathies”) in which patients can develop HCM [114-116].  Noonan (NS), Costello (CS), 
cardiofaciocutaneous syndrome (CFCS), and LEOPARD (LS) syndromes all have overlapping features of 
developmental delay, short stature, craniofacial defects, gastroesophageal dysmotility, and cardiac 
defects (including HCM) [116].  In 2001, it was discovered that gain-of-function missense mutations in 
SHP2 (encoded by PTPN11) accounted for nearly 50% of cases of Noonan syndrome [117], and nearly 
all patients with LEOPARD syndrome were found to harbor distinct dominant-negative mutations in the 
same gene [115, 118, 119].  In recent years, mutations in KRAS, NRAS, SOS1, RAF1, BRAF, MEK1, 
MEK2, SHOC2, and CBL have all been uncovered in patients with one of these “RASopathy” syndromes 
[115]. 
 Interestingly, a cardiac-specific activated RAS mouse model actually pre-dated the discovery of 
the first mutation in SHP2.  When oncogenic human HRAS was expressed in vivo in mouse 
cardiomyocytes under the control of the MLC-2v promoter, the result was a marked hypertrophic 
response, characterized by diastolic dysfunction, increased systolic Doppler velocities, intraventricular 
pressure gradients, increased expression of pathological markers, and myocyte disarray characteristic of 
human HCM [120, 121].  Additionally, when this gene was expressed postnatally under the control of the 
alpha-MHC promoter, mice developed significant hypertrophy and postnatal heart failure, presumably the 
result of impaired sarcoplasmic reticulum calcium uptake.  Surprisingly, these mice did not show any 
activation of ERK1/2 or Akt signaling, suggesting the possibility that RAS can activate additional 
pathways. 
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The discovery of the “RASopathy” mutations inevitably led to the creation of more specific mouse 
models attempting to recapitulate the various syndromes and to determine the downstream signaling 
mechanisms responsible for the pathophysiology.  Approximately 20% of patients with NS have HCM, 
and the likelihood of developing HCM is highly dependent on the particular mutation.  Less than 10% of 
patients with SHP2 mutations and only 20% of patients with SOS1 mutations develop HCM, while HCM is 
found in nearly 95% of patients with RAF1 mutations, and mouse models recapitulate these trends [122-
124].  Mice carrying a NS-associated mutation in SHP2 demonstrate specific ERK1/2 activation that was 
both necessary and sufficient during cardiac development to induce congenital heart defects, although 
this mutation was not associated with HCM [124].  In addition, induction of this gain-of-function mutation 
postnatally led to increased ERK1/2 activation in heart, but this was not associated with any cardiac 
pathology [124], indicating that postnatal activation of ERK1/2 signaling is not sufficient to induce 
hypertrophy or cardiac defects.  Meanwhile, mice carrying the NS-associated SOS1 mutation develop 
pathological LV hypertrophy through activation of ERK1/2 and Stat3, and cardiac defects were prevented 
through inhibition of the MEK pathway [123].  A third mouse model of NS containing a gain-of-function 
mutation in RAF1 is highly associated with the development of HCM, and these pathological effects are 
reliant on enhanced MEK-ERK activity [122].   What is unclear regarding these three models is why 
enhanced ERK1/2 activation appears to be necessary and sufficient for HCM in RAF1 mutants, but not in 
SHP2 mutants.   
In an attempt to better elucidate the role of ERK1/2 in the development of hypertrophy, a 
transgenic mouse model was used that overexpresses activated MEK1 in the heart.  This led to activation 
of ERK1/2 signaling and concentric hypertrophy with impaired diastolic function, enhanced systolic 
function, and upregulation of the pathological markers ANP, BNP, skeletal -actin, and -MHC, 
suggesting that ERK1/2 activation is sufficient to induce hypertrophy [125].  However, a recent study 
demonstrated that ERK1/2 is not necessary for hypertrophy development per se, but rather for regulating 
the balance between concentric and eccentric hypertrophy [126].  Mice lacking both ERK1 and ERK2 in 
the heart developed spontaneous cardiac hypertrophy with aging and also in response to angiotensin 
II/phenylephrine infusion, but close inspection of cardiomyocytes revealed that double null myocytes 
lengthen and become thinner, leading to eccentric growth of the heart.  In contrast, myocytes from hearts 
15 
 
expressing activated MEK1 to induce ERK1/2 signaling increased in width but not length, consistent with 
concentric hypertrophy [126].  Therefore, ERK1/2 signaling is not necessary for the development of 
hypertrophy, but it may affect the type of hypertrophy that results. 
In contrast to NS, HCM is much more commonly associated with LS, which is characterized by 
dominant negative mutations that decrease the catalytic activity of SHP2 [114, 115].  Mice harboring one 
of the most common mutations in Ptpn11 (Y279C) develop evidence of hypertrophic cardiomyopathy 
[127].  Additionally, mice overexpressing a cardiomyocyte-specific LEOPARD syndrome-associated loss-
of-function mutation in SHP2 (Q510E) embryonically undergo significant cardiac hypertrophy, 
cardiomyocyte disarray, and depressed contractile function; induction of this mutated SHP2 postnatally 
did not result in HCM [128].  Both of these models showed increased Akt and mTOR activity, and HCM 
was reversed by treatment with rapamycin (mTOR inhibitor) [127-129].  The role of the PI3K/Akt pathway 
in cardiac hypertrophy will be discussed in more detail below. 
What is clear from the “RASopathies” is that mutations within the same pathway can lead to very 
different (but also very similar) results.  NS-associated gain-of-function mutations all induce activation of 
the ERK1/2 pathway, but not all of the mutations lead to HCM.  Additionally LS-associated mutations 
have the opposite effect on SHP2 (dominant negative, or loss of function), are more likely to result in 
HCM through activation of the Akt/mTOR pathway.  Finally, mouse models utilizing oncogenic human 
HRAS develop HCM without activation of either ERK1/2 or Akt, suggesting that another nonclassical 
pathway may be involved.  Regardless of the final mechanism, it is evident that components immediately 
downstream of receptor tyrosine kinases (like FGFRs) are strongly implicated in the pathogenesis of 
hypertrophic cardiomyopathy.  As will be discussed in chapter three, our lab has created an inducible 
cardiomyocyte-specific constitutively-active FGFR1 mouse model that rapidly develops HCM when 
induced in the adult heart.  Although this HCM develops independent of ERK1/2 and Akt activation, based 
on the studies discussed above, it is likely that increased RAS activation is involved in the pathogenesis.  
PI3K-Akt Signaling in Physiological versus Pathological Hypertrophy.  In addition to 
activation of the Ras-MAPK pathway, phosphorylation of FRS2 and recruitment of GRB2 can also to the 
formation of another complex involving GRB2-associated binding protein 1 (GAB1) and activation of the 
PI3K-Akt pathway [21].  Evidence suggests that insulin-like growth factor-1 (IGF1) and PI3K-Akt signaling 
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mediate the development of physiological hypertrophy.  Long-term training results in increased levels of 
free serum IGF-1 [130], and transgenic mice overexpressing the IGF1 receptor (IGF1R) specifically in 
cardiomyocytes develop compensated physiological hypertrophy that is dependent on signaling through 
PI3K(p110) [131].  Further support for the involvement of the IGF1-PI3K-Akt signaling pathway 
exclusively in the development of physiological hypertrophy comes from knockout studies, in which mice 
lacking PI3K activity, Akt1 or IGF1R failed to develop exercise-induced hypertrophy, but still developed 
pathologic hypertrophy in response to pressure overload [3, 132-135].  Thus IGF1R and PI3K are both 
necessary and sufficient for physiologic but not pathologic hypertrophy. 
Despite substantial evidence that IGF-1-mediated Akt activation is necessary for the development 
of physiologic hypertrophy, studies examining the role of Akt are less clear.  While overexpression of the 
E40K (constitutively-active) Akt1 mutant results in physiologic hypertrophy (mild hypertrophy, enhanced 
contractility, no signs of cardiac pathology) [136], overexpression of myristoylated or phosphomimetic 
forms of Akt1 lead to pathologic hypertrophy (massive cardiac enlargement, impaired contractile function 
and interstitial fibrosis) [137, 138].  Yet another study demonstrated that acute activation of Akt1 resulted 
in adaptive hypertrophy with preserved contractility, while chronic activation resulted in a dilated 
cardiomyopathy with impaired cardiac function [139, 140].  These findings, in addition to those discussed 
above that LS-associated HCM is dependent on activation of Akt signaling, suggest the potential for 
overlapping mechanisms between physiologic and pathologic hypertrophy, further complicating our 
understanding of these processes. 
 
G. Conclusions 
 The Ras-MAPK-ERK1/2 and PI3K-Akt pathways highlighted above are only two of several 
pathways that can be activated following FGFR dimerization and autophosphorylation.  FGF binding has 
also been shown to activate several other pathways that are strongly implicated in cardiac hypertrophy 
and postnatal ventricular remodeling, including the p38 and JNK MAPK pathways, as well as the PLC 
pathway, which leads to activation of protein kinase C and increased cytosolic calcium [21, 141, 142].  
The fact that FGFs are capable of activating so many different hypertrophy-inducing pathways 
underscores the necessity for further research examining the role of this growth factor family in the 
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postnatal heart.  Thus far, most research has focused on FGF2.  Limited studies have examined the roles 
of other FGF ligands or attempted to define the necessary cellular targets of FGF signaling.  As such, my 
thesis work aims to increase understanding of FGF signaling in the adult heart, with the goal of better 
characterizing this pathway’s involvement in ventricular remodeling, specifically hypertrophy. 
 
H. Disclosure of co-authored works. 
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models were provided by KC Yang in the lab of Jeanne Nerbonne. 
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Figure 1.1 FGF Signaling Pathway.  FGF ligands and heparin sulfate proteoglycans bind to the FGF 
receptors, causing receptor dimerization and activation through autophosphorylation.  FGF signaling can 
then proceed via three main pathways: Ras-MAPK, PI3K-Akt, or PLC.  Recreated from [21, 143].   
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Chapter 2 
Altered Gene Expression of FGF Ligands and Receptors in Postnatal Cardiac Remodeling 
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A. Introduction 
FGF2 has been clearly shown to be a cardioprotective factor involved in cardiac remodeling 
following stress or injury to the heart.  In pressure overload models, it contributes to cardiomyocyte 
hypertrophy, while in MI models, it also causes increased fibroblast proliferation, prevents infarct 
expansion, and preserves cardiac function [31, 77, 85, 97].  Other FGF ligands, such as FGF1 and FGF9, 
and signaling pathways activated downstream of FGF receptors have also been implicated in postnatal 
cardiac remodeling.  Additionally, pilot studies by Kory Lavine, a previous graduate student in our lab, 
utilizing an inducible cardiomyocyte-specific FGF9-overexpressing mouse line suggested that this ligand 
may play a role in the development of fibrosis in the adult heart.  Induction of FGF9 overexpression 
concurrently with pressure-overload (TAC) resulted in a much more severe phenotype and rapid 
progression to heart failure (Figure 2.1).  FGF9 has also been shown to be downregulated following 
LVAD placement in failing human hearts, suggesting that its expression is increased during pathological 
ventricular remodeling [99].  This led to the hypothesis that FGF9 expression may be increased following 
cardiac injury and that it is involved in the induction of fibrosis in pathological remodeling. 
Furthermore, FGF2 is the only ligand that is well characterized in the adult heart.  Very little is 
known regarding what ligands and receptors are expressed in the adult heart and how their expression 
changes following injury or stress.  Also, despite the fact that FGFs are known to activate PI3K signaling 
[21], very little work has been done investigating whether FGF signaling plays a role in physiological 
remodeling.  To better understand when and how FGF signaling may be involved in postnatal cardiac 
remodeling, I wanted to determine how gene expression changes with different types of pathological or 
physiological stressors.  What are the commonalities between different types of injury, and perhaps more 
importantly, what are the significant differences between pathological and physiological remodeling?   
Finally, due to the fact that knockout of Fgfr1 is embryonic lethal [69, 70], very few studies have 
examined the role of this (or other) receptor(s) in the adult heart.  As mentioned above, FGF2 has been 
shown to cause cardiomyocyte hypertrophy, as well as fibroblast and endothelial cell proliferation 
following MI [97], but it is not known whether this is a direct effect on each cell type or an indirect effect 
through one cell type that serves as a signaling center.  As such, I started to address the potential cell-
specific targets of FGF2 and downstream signaling mechanisms involved in cardioprotection, using a 
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tamoxifen-inducible cardiomyocyte-specific double knockout of Fgfr1 and Fgfr2 (αMHC-CreER, FGFR1
f/f
, 
FGFR2
f/f
, R26R, or MHC-CreER DCKO) and assess the response to injury from myocardial infarction 
(MI). Future completion of these studies by others in our lab will provide essential knowledge about cell-
types that would be expected to show a beneficial response to FGF signaling versus those cell-types in 
which FGF signaling would lead to further pathological damage. They will facilitate future studies to 
address the mechanisms that regulate FGF activity in the context of physiological and pathological 
challenge. This knowledge will be essential to improve the design and implementation of FGF-based 
therapies for the treatment of human CVD.  
 
B. Results 
Inducible, Cardiac-Specific FGF9 Overexpression.  Our lab has shown previously that FGF9 is 
essential to embryonic cardiac growth [36], and therefore we hypothesized that FGF9 may also be 
important in regulating postnatal cardiac growth or may be cardioprotective after injury, similar to FGF2.  
To investigate the role of FGF9 in the adult heart, our lab has utilized the doxycycline-regulatable TET-on 
system with the αMHC-rtTA mouse line.  Expression of the reverse tetracycline transcriptional activator 
(rtTA) from the αMHC promoter leads to cardiomyocyte-specific expression of the rtTA protein [144].  To 
determine the effects of FGF9, our lab generated a tetracycline response element (TRE)-drivable FGF9-
Ires-GFP transgene, which has been characterized previously [145].  Pilot studies presented in the thesis 
of Kory Lavine demonstrated that overexpression of FGF9 in the adult heart followed by pressure 
overload was severely maladaptive and led to rapid progression to heart failure (Figure 2.1).  We 
hypothesized that FGF9 may be involved in more pathological aspects of remodeling, such as in the 
fibrotic response, and I thus continued experiments with this mouse line.  Further characterization of this 
model revealed that after three weeks of transgene induction with doxycycline chow, double transgenic 
hearts had significantly reduced diastolic LV chamber dimension (as represented by LV internal diastolic 
diameter, 3.87 vs. 4.12 mm, p=0.02) (Figure 2.2A) and significantly increased E/e’ ratios (46.6 vs. 29.7, 
p=0.05)  (Figure 2.2B).  The ratio of early mitral inflow velocity (E) to early diastolic mitral annular velocity 
(e’) is well established as the best parameter to estimate LV filling pressure [146], so the significant 
elevation of this ratio is highly suggestive of a diastolic defect (impaired relaxation) in hearts 
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overexpressing FGF9.  Despite the apparent diastolic dysfunction, systolic function, as measured by 
ejection fraction, is maintained in double transgenic mice (Figure 2.2C). 
Following echocardiography, hearts were harvested for histological analysis, which revealed 
increased perivascular and interstitial fibrosis in double transgenic hearts (Figure 2.3), as well as 
quantitative RT-PCR analysis (Figure 2.4).  Analysis of gene expression revealed that three weeks of 
DOX induction was sufficient for a 344-fold increase in Fgf9 expression in double transgenic hearts 
(p=0.001) (Figure 2.4A).  This degree of FGF9 overexpression resulted in significantly increased 
expression of Fgf2 (2.4-fold increase, p<0.001) and Fgfr1 (1.9-fold increase, p=0.02), while decreasing 
expression of Fgf16 (2.5-fold decrease, p<0.001) and Fgf10 (3.2-fold decrease, p=0.10) (Figure 2.4B).  
Markers of pathological remodeling are relatively unchanged, with the exception of Col3a1, which was 
significantly increased by FGF9 overexpression (2.9-fold increase, p=0.03) (Figure 2.4C).  In addition to 
Col3a1 upregulation, significantly increased expression of both Tgf2 and 3 (Tgf2: 2.5-fold increase, 
p=0.02; Tgf3: 1.7-fold increase, p=0.03) supports the histological finding of increased fibrosis in double 
transgenic hearts [147].  Intriguingly, expression of PdgfA and B, which also play a critical role in the 
development of fibrosis similar to TGFs [147], are decreased in double transgenic mice (PdgfA: 1.7-fold 
decrease, p=0.01; PdgfB: 2.3-fold decrease, p=0.06) (Figure 2.4E).  Meanwhile, decreased expression of 
VegfA and VegfR1/Flt1 (VegfA: 1.7-fold decrease, p=0.05; VegfR1/Flt1: 1.3-fold decrease, p=0.17) 
suggest the possibility that FGF9 overexpression may suppress angiogenesis (but at the very least does 
not increase angiogenesis) (Figure 2.4E). 
Taken together, these results strongly implicate FGF9 in the activation of fibroblasts and 
maladaptive fibrotic remodeling in the heart.  These findings are in stark contrast to a recent publication 
that demonstrated enhanced vascularization and cardiac hypertrophy with normal diastolic function 
following cardiac-specific overexpression of FGF9 [100], and thus it is evident that further analysis is 
necessary to elucidate the role that this ligand plays in adult cardiac remodeling.  Based on our model of 
FGF9-overexpression, we hypothesized that FGF9 expression may be increased in hearts undergoing 
pathological remodeling. 
FGF Expression in Physiological Hypertrophy.  Samples were obtained from KC Yang in 
Jeanne Nerbonne’s lab to analyze gene expression changes in two different models of physiological 
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hypertrophy.  One group of eight- to 10-week-old mice were subjected to swim training for four weeks to 
induce physiological hypertrophy (n=6), while a second group of mice contained cardiac-specific 
constitutively-active PI3K, a genetic model of physiological hypertrophy (n=6) [148].  As expected, neither 
exercise nor caPI3K induced an increase in ANP expression (Figure 2.5A).  Intriguingly, I observed a 
significant increase in MHC in hearts expressing caPI3K (3.7-fold increase, p=0.03), in agreement with 
other published studies [148]. 
There were other important differences between exercise-induced and genetically-induced 
physiological hypertrophy, underscoring the complexity of this remodeling process.  Fgf2 expression was 
significantly downregulated in exercise-induced hypertrophic hearts (1.6-fold decrease, p=0.003), but 
unchanged in hearts from caPI3K mice.  In addition, Fgf10 was slightly, but not significantly, upregulated 
in exercise-induced hearts (1.2-fold increase, p=0.16), while Fgf9 showed a similar trend in caPI3K hearts 
(1.2-fold increase, p=0.12).  Additionally, Fgfr1 was significantly downregulated in exercise-induced 
hypertrophy (1.2-fold decrease, p=0.02), but significantly increased in caPI3K-induced hypertrophy (1.7-
fold increase, p<0.001) (Figure 2.5C). 
One change that was common to both models of physiological hypertrophy was a significant 
increase in Fgf16 expression.  Fgf16 was increased 1.2-fold in exercise-induced hearts (p=0.009) and 
1.4-fold in caPI3K hearts (p=0.01) (Figure 2.5B).  There were no significant changes in Fgfr2 or Fgfr3 
(Figure 2.5C). 
As noted above, this experiment highlighted some significant differences between actual 
physiological hypertrophy (as induced through exercise) and an established genetic model of 
physiological hypertrophy (utilizing constitutively-active PI3K).  Even in this limited screen of FGF ligands 
and receptors, there were potentially important differences in gene expression that could be useful in 
further investigating the distinctions between pathological and physiological remodeling.  No study to date 
has examined the necessity for FGF signaling in physiological hypertrophy, and based on the results of 
this screen, it would be worthwhile to examine the response to exercise in FGF2-knockout and FGF2-
transgenic animals, as well as in FGF16-knockout and –transgenic mice.  
FGF Expression in Pressure Overload-Induced Pathological Hypertrophy. To induce 
pathological remodeling, 8- to 10-week-old wild-type mice were subjected to ascending aortic constriction 
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(AAC) to cause significant pressure overload in the LV (performed by Carla Weinheimer in the 
Washington University Mouse Cardiovascular Phenotyping Core, http://mcpc.wustl.edu/).  One week 
following surgery, hearts were harvested for gene expression analysis using quantitative RT-PCR (Figure 
2.6).  While there were trends toward upregulation of markers of pathological remodeling (Figure 2.6B-D), 
only Fgf16 expression was significantly changed (2-fold decrease, p=0.02) (Figure 2.6A).  The lack of 
significant changes in other genes studied was likely the result of the small sample size in this pilot 
experiment (nAAC=2). 
FGF Expression in Angiotensin II-Mediated Pathological Remodeling. It has long been 
known that the use of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers 
is extremely beneficial in prolonging the progression of congestive heart failure.  However, the 
mechanism by which angiotensin II (AngII) contributes to maladaptive heart remodeling is largely 
unknown.  Several studies have shown that overactivation of the renin-angiotensin system (RAS) leads to 
cardiac fibrosis and diastolic dysfunction with no overt cardiac hypertrophy.  In a mouse with a 
constitutively active form of AT1a, an angiotensin II receptor, the major cardiovascular modification was 
not cardiac hypertrophy or excessively high blood pressure, but rather, fibrosis, which appeared in early 
adulthood and progressed throughout the life of the mouse [149].  The cardiac fibrosis was primarily 
perivascular with some interstitial fibrosis, and the amount of fibrosis paralleled the functional cardiac 
alterations that occurred in these mice by 5 months of age (diastolic dysfunction with subsequent 
evolution toward heart failure) [149].  Similarly, mice with cardiac-specific expression of a transgene 
fusion protein that releases AngII from cardiomyocytes (without involvement of systemic RAS) had 
increased collagen deposition and no hypertrophy in the heart under basal conditions [150].  These mice 
were subjected to ligation of the LAD to induce an MI, and the transgenic mice had a more profound 
hypertrophic response, a significantly increased LV internal diastolic diameter, and a significantly 
decreased ejection fraction compared to their WT littermates [150].  Furthermore, mice with a targeted 
deletion of the angiotensin II receptor, AT1, had virtually no interstitial fibrosis in response to severe 
chronic aortic regurgitation, a model of LV volume overload.  In contrast, WT mice in this same 
experiment had extensive progressive interstitial fibrosis that led to severe diastolic dysfunction and 
congestive heart failure [151]. 
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These results are very similar to what we have seen when FGF9 expression is induced in the 
adult myocardium, as described above.   As a result, I hypothesized that there is a link between the 
cardiac fibrosis seen in these models of AngII and FGF9 overexpression.  It has been demonstrated that 
angiotensin II is able to upregulate expression of FGF2, FGFR1, and HSPG in cultured human cardiac 
smooth muscle cells [152], and thus is may be possible that AngII also increases the expression of FGF9.   
To determine if there is a connection between AngII- and FGF9-mediated fibrosis, we inserted 
mini-osmostic pumps containing angiotensin II (2ug/kg/min) into wild-type mice, allowing AngII to be 
released at a rate of 0.5 l/h for 14 days.  Echocardiography was performed at the end of the two-week 
infusion to assess in vivo LV mass and cardiac function (Figure 2.7A and B).  Angiotensin II resulted in a 
moderate, but insignificant, increase in LV mass index (6.3 vs. 4.0 mg/g, p=0.2) (Figure 2.7A) and a 
significant increase in systolic function, as measured by ejection fraction (EF, 0.75 vs. 0.59, p=0.002).  In 
agreement with in vivo measurement of LV mass, postmortem assessment of cardiac mass, determined 
by the ratio of heart weight (biventricular mass) vs. body weight (HW/BW ratio), was significantly 
increased in mice that received AngII compared to vehicle-treated controls (5.9 vs. 4.6 mg/g, p=0.02) 
(Figure 2.7C).  Additionally, histologic analysis displayed increased fibrosis in mice treated with AngII 
(Figure 2.7D).  Furthermore, analysis of gene expression using quantitative RT-PCR revealed significant 
reduction in the expression of Fgfr2 (1.5-fold decrease, p=0.005), Fgf7 (1.4-fold decrease, p=0.02), and 
Fgf16 (2.9-fold decrease, p=0.004), with near significant reduction of Fgf10 (3.4-fold decrease, p=0.06) 
(Figure 2.8 A and B).  There were trends toward upregulation of Anp, Bnp, Col3a1, and Tgf3 (Figure 2.8 
C and D).  Intriguingly, expression of MHC was not increased despite the appearance of pathological 
hypertrophy (Figure 2.8C). 
Myocardial Infarction.  Eight- to 12-week-old mice were subjected to LAD ligation to induce 
myocardial infarction (performed by Carla Weinheimer in the Washington University Mouse 
Cardiovascular Phenotyping Core, http://mcpc.wustl.edu/) [153, 154].  One week following MI, hearts 
were removed and dissected into two pieces, infarcted tissue and non-infarcted tissue.  Both pieces likely 
included infarct border zone.  RNA was extracted and quantitative RT-PCR was utilized to compare gene 
expression between non-surgical controls, non-infarcted myocardium, and infarcted myocardium.  
Consistent with published studies [107, 110], Fgf2 expression was significantly increased in infarcted 
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myocardium (1.8-fold versus nonsurgical control, p=0.03) (Figure 2.3A).  Fgfr1 and Fgfr2, and a 
downstream effector of FGF signaling, Etv4 (Pea3), were also significantly upregulated in the infarct 
region one week following MI (Fgfr1: 5.6-fold increase, p=0.001; Fgfr2: 25.9-fold increase, p=0.02; 
Etv4/Pea3: 11.3-fold, p=0.004).  Fgfr2 was also significantly increased to a lesser degree in the non-
infarcted myocardium (9.5-fold increase, p=0.03), while Fgfr1 and a different downstream effector, Etv5 
(Erm), were nearly significantly increased (Fgfr1: 2.2-fold increase, p=0.06; Etv5/Erm: 2.0-fold increase, 
p=0.06) (Figure 2.3B). 
  Surprisingly, there was significant downregulation of Fgf9 and Fgf16 in both the infarcted and 
non-infarcted myocardium compared to nonsurgical controls (Fgf9 infarct: 5-fold decrease, p<0.001; Fgf9 
non-infarct: 3.3-fold decrease, p=0.004; Fgf16 infarct: 12.5-fold decrease, p<0.001; Fgf16 non-infarct: 3.3-
fold decrease, p=0.001) (Figure 2.3A).  Gene expression was present, but unchanged for Fgfr3, Fgf7, 
Fgf10, and Fgf17.  Expression of Fgf20 and Fgfr4 could not be detected, and other FGF ligands were not 
examined. 
Expression of other genes involved in cardiac remodeling are presented in Figure 2.3 (C-E).  All 
pathological markers were trending towards upregulation, with significant increases noted for Anp in the 
non-infarcted myocardium (9.6-fold increase, p=0.04) and Col1a1 in the infarcted tissue (3.6-fold 
increase, p=0.009) (Figure 2.3C).  Meanwhile, TGF1-3 were all significantly upregulated in the infarct 
region (TGF1: 2.6-fold increase, p=0.05; TGF2: 3.5-fold increase, p=0.04; TGF3: 7.4-fold increase, 
p=0.005), and non-significantly increased in non-infarcted tissue (Figure 2.3D).  Additionally, there was a 
trend towards upregulation of PdgfA in both the infarcted and non-infarcted wall, while PdgfC was 
significantly upregulated in the infarct zone (12.7-fold increase, p=0.05) (Figure 2.3 E). 
I have also noted significant upregulation of the epicardial marker Tbx18 and increased 
expression of the EMT marker Slug in the infarct region (Figure 2.3F), consistent with previous studies 
[155]. Published studies have shown that myocardial and vascular precursor cells reside within the 
epicardium, that these cells can migrate into the damaged tissue following MI  [156, 157], and that FGF2 
can induce epicardial EMT in the developing chick heart
 
[60]. I hypothesize that one function of FGF2 
upregulation in response to MI is signaling to FGFRs in the epicardium to stimulate EMT and migration of 
EPDCs into the infarcted tissue to promote healing.  Similar to the mechanism proposed in zebrafish to 
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regenerate heart tissue [158], EPDCs could then differentiate into vascular and myocardial progenitor 
cells and help to repopulate and repair infarcted tissue. However, it is additionally possible that FGF2 
signals directly to the cardiomyocyte where it could have a direct cardioprotective role by inducing 
hypertrophy or promoting cell survival, or to the endothelial or perivascular cell, where it could function in 
neo-angiogenic pathways that are necessary for the myocardial response to injury.  Another, more likely, 
alternative is that one of these cell types (epicardial, endothelial, fibroblast, or myocyte) receives the FGF 
signal and serves as a signaling center, releasing other factors that promote the remodeling effects in 
other cells (Figure 2.10). 
While one recent study has constitutively overexpressed an activated FGFR2 in endothelial cells 
and shown an improved response to MI [112], no studies have addressed the potential cellular targets of 
FGF2 (or any other FGF) in the mature heart by examining cell-specific requirements for FGFR 
expression/function in response to injury or physiological challenge.  
Response to MI in a Tamoxifen-Inducible Cardiomyocyte-Specific FGFR1/2 Double 
Conditional Knockout.  To determine if FGF signaling in the cardiomyocyte is directly responsible for 
any of FGF2’s cardioprotective effects, I have used a tamoxifen-inducible cardiomyocyte-specific 
FGFR1/2 double conditional knockout mouse line (αMHC-CreER, FGFR1
f/f
, FGFR2
f/f
, R26R, or MHC-
CreER DCKO) (Figure 2.11A). Twelve- to fourteen-week-old MHC-CreER DCKO mice and their littermate 
FGFR1
f/f
, FGFR2
f/f
, R26R (DFF) controls, as well as αMHC-CreER, R26R control (Cre control) mice, were 
injected IP with 40mg/kg tamoxifen daily for six days to induce Cre activity. One week later, mice were 
harvested either for examination of heart weight-to-body weight (HW/BW) ratios, β-galactosidase staining, 
and  quantitative RT-PCR analysis, or subjected to ligation of the left anterior descending (LAD) artery to 
induce myocardial infarction (performed by Carla Weinheimer in the Washington University Mouse 
Cardiovascular Phenotyping Core, http://mcpc.wustl.edu/).  
One week following tamoxifen injections, MHC-CreER DCKO mice expressed LacZ in nearly all 
cardiomyocytes, with no expression seen around the vasculature, in the epicardium, or in DFF controls, 
indicating sufficient Cre activation following six days of tamoxifen injections (Figure 2.11B). MHC-CreER 
DCKO and littermate control mice (with or without Cre) had comparable HW/BW ratios (Figure 2.11C), 
indicating that one week following tamoxifen injections, there is no apparent tamoxifen- or Cre-induced 
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toxicity and that acute inactivation of FGF receptors 1 and 2 from the myocardium does not affect cardiac 
mass.  
Eight- to 12-week-old mice received MI surgery one week following tamoxifen injections, and 
were followed by echocardiography at one week and one month post-MI. Serial short-axis slices were 
used to measure ejection fraction and percentage of infarcted tissue at both time points using 
VisualSonics Vevo770 software. MHC-CreER DCKO mice showed a trend towards decreased ejection 
fractions and increased infarct sizes compared to their littermate controls (Figure 2.12C and D). When 
harvested one month post-MI, DCKO mice had elevated lung weight-to-body weight ratios (LW/BW) 
(Figure 2.12A), as well as higher expression of both Anp, Bnp and βMHC in non-infarcted tissue (opposite 
wall) compared to DFF littermate controls (Figure 2.13), indicating a higher degree of heart failure in 
these mice.  Though myocyte size was not measured in these experiments, the fact that MHC 
expression increases significantly suggests that the hypertrophic remodeling program is still induced.  As 
a result, I hypothesize that cardiomyocyte FGF receptors play a role in cardiomyocyte survival rather than 
hypertrophy, and that increased cell death may be responsible for the larger infarct sizes and poorer 
function post-MI. 
These studies were eventually discontinued for several reasons.  Progress was slowed 
significantly with higher than normal mortality for MI studies for both genotypes (~50%), a problem that 
was encountered by other mouse lines in our lab undergoing different cardiac surgeries, such as closed-
chest ischemia-reperfusion.  During the troubleshooting process, we determined that transfer stress was 
the most likely cause of our mortality issues, and have since moved our cardiac colony adjacent to the 
Mouse Cardiovascular Phenotyping Core, resulting in normal rates of postsurgical mortality.  Meanwhile, 
the closed-chest ischemia-reperfusion model had been recently established in the Mouse Cardiovascular 
Phenotyping Core, and since this model was more clinically relevant [159], we decided to continue future 
experiments using this model instead of the chronic MI model. 
 
C. Discussion  
 As mentioned previously, most studies examining FGF signaling in the adult heart have revolved 
around FGF2, but very little work has been done investigating other FGF ligands or receptors in the 
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postnatal heart.  It was the goal of these experiments to increase our knowledge of how FGF signaling 
molecules change in different models of cardiac remodeling, both pathological and physiological.  Notable 
findings from these gene expression analysis experiments are summarized in Table 2.1.  The most 
striking findings were the very dramatic changes in Fgf16 expression, in addition to the fact that the 
expression pattern was reversed between physiological and pathological hypertrophy.  Fgf16 expression 
was significantly increased following exercise- or caPI3K-induced hypertrophy, but significantly decreased 
in every pathological model examined (pressure overload, AngII, MI).  Changes in Fgf16 expression were 
far less variable than changes in other genes, achieving significant results in some cases with a sample 
size of only two animals. 
Recent publications have begun to examine the role of FGF16 in the postnatal heart.   Lu et al. 
examined the expression and functions of FGF16 and found that FGF16 expression markedly increases 
during the early neonatal period compared to expression levels in the embryonic heart, and that these 
high levels of expression persist into adulthood [39].  Using cultured neonatal cardiomyocytes, they 
discovered that FGF16 abrogates FGF2-induced myocyte proliferation and upregulation of cell cycle 
genes, but that FGF16 treatment alone has no effects on cardiomyocytes or cell cycle gene expression 
[39].  The authors note that the increasing FGF16 expression in cardiomyocytes during the neonatal 
period corresponds with the loss of proliferative capacity in these cells.  Therefore they postulate that 
FGF16 negatively regulates proliferation of neonatal cardiomyocytes, possibly through receptor 
competition with FGF2 or via downstream effects on PKC signaling [39].   
This finding is very interesting, because it suggests the possibility that FGF16 may also 
negatively regulate growth, or hypertrophy, of adult cardiomyocytes.  Intriguingly, my work has indicated 
that this growth factor is significantly downregulated when the heart is stressed, and in situations where 
FGF2 has been shown to be necessary for remodeling.  Thus, I hypothesize that FGF16 opposes the 
actions of FGF2 under normal conditions, and that its expression is downregulated when the heart is 
under stress to allow FGF2-mediated hypertrophy and cardiac remodeling to occur in order to preserve 
heart function.   
While expression of FGF9, which is closely related to FGF16 [160], follows similar trends, it is 
clearly not as tightly regulated as FGF16.  Additionally, despite our hypothesis that FGF9 contributes to 
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pathological fibrotic remodeling, we did not see upregulation of this ligand in any of the heart failure 
models, suggesting that it is not an essential signal for the development of fibrosis.  Studies are being 
continued in our lab to further address the roles of FGF9 and FGF16 in the postnatal heart. 
Another interesting finding from this gene expression analysis was the significant upregulation of 
both Fgfr1 and Fgfr2 one week following myocardial infarction in both the infarcted and non-infarcted 
myocardium.  Very little is known about the in vivo expression patterns of FGF receptors and ligands in 
adult heart tissue due to a lack of suitable antibodies and difficulty immunostaining adult cardiac sections.  
In addition, despite the clear necessity for FGF2 in ventricular remodeling, no study has addressed the 
potential cellular targets of FGF2 (or other FGF ligands) in the mature heart by examining cell-specific 
requirements for FGFR expression/function in response to injury or physiological challenge.  We 
hypothesized several models (discussed above and presented in Figure 2.10) of direct and indirect 
signaling, and I began breeding our DFF mouse line into various tissue-specific Cre lines, such as the 
MHC-CreER [161], Gata5-Cre [162], and Tie2-Cre [163] lines, in order to test the different models.  
MHC-CreER DCKO mice showed trends toward increased infarct sizes, poorer function, and higher levels 
of pathological gene expression in the MI model, suggesting that FGF signaling is necessary in 
cardiomyocytes for proper remodeling and maintenance of function after injury, although the precise 
mechanism is still being investigated using the more clinically relevant closed-chest ischemia-reperfusion 
model.  Based on these results, we also hypothesized that FGFR gain-of-function in cardiomyocytes 
would be cardioprotective following cardiac injury.   
Finally, the findings presented in this chapter also suggest potential mechanisms for regulation of 
FGF signaling in the adult heart.  As discussed in the introduction, FGFs are potent mitogenic factors that 
are essential for embryonic cardiac growth and capable of stimulating proliferation and cell growth in 
cultured myocytes.  As such, it is only logical that FGF signaling would be repressed (or maintained at low 
levels) in the adult heart in order to maintain proper cardiac size, and that this pathway would be induced 
following injury or stress to allow for postnatal cardiac growth.  This would explain why cardiac-specific 
overexpression of FGF2 does not result in spontaneous hypertrophy; however, the mechanisms for this 
repression are unknown.  By combining the findings of these studies with previously published work, I 
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propose four potential models by which FGF signaling can be kept in check in the postnatal heart until 
required following stress, presented in Figure 2.14.   
The first model states that FGF2 is sequestered in the cell in which it is made and only released 
following injury.  It is well established that FGF2 is not efficiently secreted [23], and further support for this 
model comes from a previous publication examining a cardiac-specific FGF2-transgenic mouse line, in 
which FGF2 protein expression was increased 25-fold, but only a 2-fold increase was observed in the 
coronary effluent [77].  It has also been demonstrated previously that FGF2 is able to stimulate the 
expression of cell cycle and hypertrophy markers in vitro in isolated ventricular myocytes [83, 164], 
suggesting that if FGF2 were available to myocytes in vivo, it would stimulate a hypertrophic response.  
Furthermore, recent work suggests that caspase-1 can mediate the secretion of FGF2, providing a 
potential mechanism for stress-induced release of this ligand [165]. 
The second model I hypothesize states that FGF2 is released from the cell but sequestered in the 
extracellular matrix until injury occurs, when it is freed to reach the target cell.  It is known that FGF2 can 
be retained in the extracellular matrix by binding to heparin sulfate proteoglycans [13, 166], but recent 
evidence also suggests that other FGF ligands, such as FGF16, can modulate the activity FGF2 [39].  
The results of my studies support a model in which FGF16 and FGF2 are tightly and reciprocally 
regulated, suggesting the possibility that FGF16 levels must be reduced in order for FGF2-mediated 
remodeling to occur.  Studies are ongoing in our lab to further investigate the interactions between FGF2 
and other FGF ligands. 
The third model proposes that regulation of FGF signaling occurs at the level of the receptors on 
the target cell; I hypothesize that receptors may be present at a low level basally with their expression 
upregulated following injury.  As discussed in chapter 1, there is conflicting evidence regarding both the 
expression of FGF receptors in the adult heart.  One study found expression of FGFR1, 2, and 4 in 
cardiomyocytes, and expression of FGFR1, 2, and 3 in the vasculature in human samples using 
immunohistochemistry [106].  In contrast, a study in rats utilizing quantitative in vitro autoradiography to 
image FGFRs that bind to a labeled FGF2 found very low levels of FGF receptor expression in the adult 
myocardium, with only the blood vessels showing a high density of receptors [107], while yet another 
study demonstrated very low, but detectable, gene expression of Fgfr1 in isolated adult rat 
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cardiomyocytes [108].  The robust increase the expression of Fgfr1 and Fgfr2 following injury in my 
studies supports the possibility that regulation of FGF signaling is at least partially mediated at the level of 
receptor expression. 
Finally, the fourth potential model purports that downstream components of the FGF signaling 
pathway are repressed basally and induced under injury conditions.  This would seemingly contradict in 
vitro studies that indicate that adult cardiomyocytes are competent to respond to an FGF signal [164], but 
one cannot refute the possibility that the act of isolating and culturing adult ventricular myocytes 
constitutes a cardiac injury capable of altering gene expression.  As such, only in vivo studies utilizing cell 
autonomous activation of FGF signaling can rule out this model.  These studies will be the focus of 
Chapter 3. 
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Figure 2.1 Over-expression of FGF9 promotes transition from hypertrophy to heart failure. (A) 
Schematic depicting timing of transgene activation and transaortic constriction (TAC). (B-D) Whole mount 
photographs of control sham (B), control TAC (C), and FGF9 over-expressing TAC (D) hearts 
demonstrating marked cardiomegaly in banded (TAC) FGF9 hearts. 4X magnification. E, Quantitation of 
LV mass index in control and FGF9 over-expressing hearts reveals that for both genotypes banded 
hearts show increased LV mass index.  Banded FGF9 over-expressing hearts have a significantly 
increased LV mass index compared to banded control hearts. (F-H) Trichrome staining of control sham 
(F), control TAC (G), and FGF9 over-expressing (H) hearts demonstrates that over expression of FGF9 
enhances cardiac fibrosis seen in control TAC hearts. I-K, Echocardiographic analysis of control sham (I), 
control TAC (J), and FGF9 over expressing (K) hearts reveals that while control sham and control TAC 
hearts display normal systolic function, FGF9 over-expressing hearts have diminished contractile function, 
K, Quantitation of fractional shortening shows that FGF9 over-expressing TAC hearts have a statistically 
significant decrease in fractional shortening compared to both control sham, control TAC, and FGF9 over-
expressing sham mice. Asterisk denotes a statistically significant difference between sham and TAC mice 
and # denotes a statistically significant difference control TAC and FGF9 over-expressing TAC mice.  
(Experiments performed and figure/legend created by Kory Lavine, a past graduate student in the Ornitz 
lab.) 
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Figure 2.2 Cardiac-specific overexpression of FGF9 in the adult heart results in diastolic 
dysfunction with preservation of systolic function.  MHC-rtTA, TRE-FGF9 double transgenic (DTG) 
and littermate controls were fed doxycycline chow for 20 days to induce transgene expression, and then 
echocardiography was utilized to measure cardiac function.  (A) Double transgenic hearts had 
significantly smaller LV internal diastolic diameter (LVIDd) than littermate controls.  (B) DTG mice also 
had significantly higher E/E’ ratios, indicating higher filling pressure compared to control hearts.  (C) 
Despite apparent diastolic defects, systolic function, as measured by ejection fraction (EF), was normal in 
DTG mice.  ncontrol=4, nDTG=5.  Error bars = standard deviation.  *p<0.05. 
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Figure 2.3 Overexpression of FGF9 in the adult heart leads to increased fibrosis.  MHC-rtTA, TRE-
FGF9 double transgenic (DTG) and littermate controls were fed doxycycline chow for 20 days to induce 
transgene expression, and then hearts were harvested for histological analysis.  Trichrome staining of 
control (left) and double transgenic hearts (DTG) reveals areas of increased perivascular and interstitial 
fibrosis, likely accounting for the diastolic defects seen on echocardiography. 
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Figure 2.4 Changes in gene expression following three weeks of cardiac FGF9 overexpression.  
MHC-rtTA, TRE-FGF9 double transgenic (DTG) and littermate controls were fed doxycycline chow for 
20 days to induce transgene expression, and then hearts were harvested for quantitative RT-PCR 
analysis.  (A) Feeding of DOX chow for 20 days leads to 340-fold upregulation in Fgf9 expression in DTG 
hearts.  (B) Overexpression of FGF9 for 3 weeks leads to significant upregulation of Fgf2 and Fgfr1, and 
significant downregulation of Fgf16.  (C) Markers of pathological cardiac remodeling are relatively 
unchanged, with the exception of Col3a1, which is significantly upregulated.  (D) Tgf1 and 2 are also 
significantly upregulated, supporting histologic findings of increased fibrosis in FGF9-overexpressing 
hearts.  (E) PdgfA expression is significantly decreased, and there is a trend towards decreased PdgfB, 
VegfA, and VegfR1, indicating that vascularization is not increased following FGF9 induction.  ncontrol=5, 
nDTG=5.  Error bars=SEM.  *p<0.05, **p<0.01, +p<0.001. 
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Figure 2.5 Different gene expression profiles from exercise-induced versus caPI3K-induced 
physiological hypertrophy models.  (A) As expected, neither model showed an increase in ANP 
expression, supporting the notion that the hypertrophy is physiological.  Constitutively-active PI3K, 
however, did induce significant upregulation of MHC, an intriguing finding that has been noted previously 
[148].  (B) Fgfr1 expression was significantly decreased in exercise-induced hypertrophy but significantly 
increased in caPI3K hearts.  (C) Fgf2 expression was significantly decreased in exercise-induced 
hypertrophy, but unchanged in hearts expressing caPI3K, while Fgf16 expression was significantly 
increased in both conditions.  n=6 for all groups.  Error bars = SEM.  *p<0.05, **p<0.01, +p<0.001. 
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Figure 2.6 Gene expression changes one week post-aortic banding.  Eight- to 10-week-old mice 
were subjected to ascending aortic constriction (AAC) to induce pressure overload and pathological 
hypertrophy.  (A) There was a slight increase in Fgf2 expression one week after aortic banding and a 
significant decrease in Fgf16 expression.  (B) There was a trend towards upregulation of markers of 
pathological remodeling, (C) Tgf expression, and (D) Pdgf expression one week after AAC.  ncontrol=3, 
nAAC=2.  Error bars=SEM.   
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Figure 2.7 Angiotensin II infusion induces hypertrophy, enhanced systolic function, and increased 
fibrosis in wild-type mice. Angiotensin II- (AngII-) containing osmotic minipumps were implanted in wild-
type mice, allowing for continual delivery of AngII for two weeks.  (A) After two weeks of AngII infusion, 
echocardiography revealed increased LV mass index, and (B) significantly enhanced systolic function.  
(C)  Postmortem analysis revealed significantly increased cardiac mass, as measured by heart weight 
(biventricular weight) to body weight ratio (HW/BW).  (D) Histological analysis using Trichrome staining 
illustrates the presence of increased fibrosis in mice that received AngII (right) compared to vehicle 
controls (left).   n=2 for both groups.  Error bars=SEM.  *p<0.05, **p<0.01. 
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Figure 2.8 Changes in gene expression following AngII treatment.  Wild-type mice were infused with 
AngII or vehicle via osmotic minipumps for two weeks, and then hearts were harvested for quantitative 
RT-PCR analysis.  (A)  Fgfr2 was significantly downregulated following AngII treatment.  (B) Fgf7 and 
Fgf16 were also significantly decreased in mice receiving AngII.  (C) Expression of Anp and Bnp are 
increased following AngII infusion (not significant), and despite the presence of hypertrophy, MHC 
expression is actually decreased (not significant).  (D)  Despite the appearance of increased fibrosis on 
histology, expression of fibrotic markers is not significantly upregulated.  n=2 for both groups.  Error 
bars=SEM.  *p<0.05, **p<0.01. 
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Figure 2.9 Altered gene expression one week following MI.  The left anterior descending artery was 
ligated to induce myocardial infarction.  Quantitative RT-PCR was used to examine gene expression of 
FGF ligands and receptors and other markers of pathological remodeling in infarcted and non-infarcted 
regions from the same heart compared to nonsurgical controls.  (A) Fgf2 is significantly increased in 
infarcted tissue, while expression of Fgf9 and Fgf16 is significantly repressed in both infarct and non-
infarct regions.  (B) Fgfr1, Fgfr2, and a downstream mediator of FGF signaling, Etv4/Pea3 are 
significantly upregulated in the infarct zone, while Fgfr2 is also significantly increased in non-infarcted 
myocardium.  (C) ANP expression is significantly increased in non-infarcted tissue, while Col1a1 is 
significantly upregulated in the infarct region.  (D) Tgf1-3 are all increased in infarcted tissue.  (E) PdgfC 
is also significantly increased in the infarct zone.  (F) There is a trend for increased expression of 
epicardial markers following MI, though only Tbx18 shows significant upregulation in the infarct region.  
ncontrol=3, nMI=4.  Error bars = SEM.  *p<0.05, **p<0.01, +p<0.001. 
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Figure 2.10 Possible Mechanisms for FGF2-Mediated Cardioprotection.  (A) I hypothesize that one 
function of FGF2 upregulation in response to MI is signaling to FGFRs in the epicardium to stimulate EMT 
and migration of EPDCs into the infarcted tissue to promote healing.  Similar to the mechanism proposed 
in zebrafish to regenerate heart tissue [158], EPDCs could then differentiate into vascular and myocardial 
progenitor cells and help to repopulate and repair infarcted tissue. (B) Another possibility is that FGF2 
signals directly to the cardiomyocyte where it could have a direct cardioprotective role by inducing 
hypertrophy or promoting cell survival, or to the endothelial or perivascular cell, where it could function in 
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angiogenic pathways that are necessary for the myocardial response to injury.  (C) Another, more likely, 
alternative is that one of these cell types (epicardial, endothelial, fibroblast, or myocyte) receives the FGF 
signal and serves as a signaling center, releasing other factors that promote the remodeling effects in 
other cells.  ECs=endothelial cells, CMs=cardiomyocytes, VSMCs=vascular smooth muscle cells, 
SEM=subepicardial mesenchyme, EMT=epithelial-mesenchymal transition. 
  
47 
 
 
Figure 2.11 Tamoxifen-inducible cardiomyocyte-specific FGFR1/2 double conditional knockout 
(MHC-CreER DCKO). (A) Schematic of the double conditional knockout system, showing that following 
tamoxifen injections (6 days, 40 mg/kg IP), Cre becomes active in cardiomyocytes and deletes floxed 
alleles of FGF receptors 1 and 2. (B) β-galactosidase staining one week following the sixth tamoxifen 
injection shows LacZ expression in nearly all cardiomyocytes, with no expression around vasculature, in 
the epicardium (DCKO R26R) or in littermate controls (DFF R26R). (C) HW/BW ratios suggest equivalent 
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cardiac mass in DCKO and littermate control (with or without Cre) mice.  Error bars=SEM.  DFF=double 
floxed-floxed (Fgfr1
f/f
, Fgfr2
f/f
), DCKO=double conditional knockout (MHC-CreER, Fgfr1
f/f
, Fgfr2
f/f
). 
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Figure 2.12 MHC-CreER DCKO mice have a poorer response following myocardial infarction. (A) 
DCKO mice have higher lung weight to body weight ratios (LW/BW), suggesting a high degree of cardiac 
dysfunction.  (B) Representative echo images illustrating larger infarct size in DCKO mice.  (C) DCKO 
hearts trend towards increased infarct sizes and (D) poorer systolic function compared to littermate 
controls at both one week and one month following MI.  Ejection fraction and % infarcted tissue were 
measured using serial short-axis echocardiographic slices and Vevo770 software. nDFF=6, nDCKO=7.  Error 
bars=SEM. 
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Figure 2.13 MHC-CreER DCKO mice show increased expression of markers of pathological 
remodeling.  One month following MI, hearts were harvested and dissected into infarcted tissue and non-
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infarcted tissue.  DCKO hearts showed trends toward increased expression of (A) Anp, (B) Bnp, (C) 
MHC, and (D) Col3a1 in both infarct and non-infarct regions.  In addition, non-surgical DCKO mice had 
significantly decreased expression of Anp compared to littermate controls (A).  Nonsurgical: nDFF=4, 
nDCKO=3; MI: nDFF=6, nDCKO=7.  Error bars=SEM.  *p<0.05 vs. respective nonsurgical controls.  #p<0.05 
vs. DFF littermate controls. 
 
 
  
52 
 
 
 
Figure 2.14 Proposed models for regulation of paracrine FGF signaling in the adult heart. We 
propose four potential models to address why FGF2 loss- and gain-of-function mice do not have a cardiac 
phenotype under homeostatic conditions. In model #1, FGF2 is sequestered in the cell in which it is made 
and only released following injury. In model #2, FGF2 is released from the cell but sequestered in the 
extracellular matrix until injury occurs, when it is freed to reach the target cell. In model #3, regulation of 
FGF signaling occurs at the level of the receptors on the target cell; we hypothesize receptors may be 
present at a low level basally with their expression upregulated following injury. Finally, in model #4, 
downstream components of the FGF signaling pathway are repressed basally and induced under injury 
conditions. 
  
53 
 
 
Table 2.1 Summary of notable gene expression changes in different models of cardiac 
remodeling.  Cells highlighted in green represent genes that were significantly upregulated, while cells 
highlighted in red represent genes that were significantly downregulated.  Note that Fgf16 expression 
displays a distinct expression pattern, in which it is upregulated in models of physiological hypertrophy 
and downregulated in models of pathological hypertrophy. 
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Chapter 3 
In Vivo Induction of Constitutively-Active FGFR1 in Adult Cardiomyocytes Leads to the Rapid 
Development of Hypercontractility and Hypertrophic Cardiomyopathy through Modulation of 
Sarcomere Mechanics 
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A. Introduction 
Hypertrophy is an adaptive mechanism by which the heart can respond to stress or injury.  In 
response to postnatal development, pregnancy, or exercise, the heart undergoes physiological 
hypertrophy, characterized by a predominant increase in myocyte length, absence of fibrosis, 
maintenance of chamber dimension, and normal cardiac function.  In response to injury or stress, such as 
a myocardial infarction or an increase in afterload due to hypertension, functional heart muscle will 
compensate with hypertrophy, which initially maintains cardiac function.  This pathological hypertrophy is 
characterized by predominantly increased myocyte width, fibrosis, decreased ventricular chamber 
volume, and eventual cardiac dysfunction and failure [2, 3]. Additionally, there is a primary myocardial 
disorder, hypertrophic cardiomyopathy (HCM), most often caused by dominant mutations in sarcomeric 
proteins.  HCM is a pathologic condition characterized by myocyte hypertrophy and disarray, fibrosis, and 
maintenance or even enhancement of systolic function [5, 167].  Many studies have attempted to 
elucidate mechanisms that result in hypertrophy, but this process remains poorly understood, particularly 
with regard to mechanisms that distinguish the advantageous physiologic hypertrophy from the 
detrimental pathologic hypertrophy. 
Previous studies have indicated that while not essential for development, FGF2 is upregulated 
and is vital to the pathologic hypertrophic response to cardiac pressure overload, as well as the 
remodeling response to chronic myocardial infarction (MI) [31, 32, 77, 97].  Fgf2
-/-
 mice develop 
significantly less hypertrophy compared with Fgf2
+/+
 mice following transverse aortic constriction (TAC) 
[32], and, compared to controls, they also show larger infarct sizes and poorer function following MI [77, 
97].  Gain-of-function studies in mice in which FGF2 is constitutively overexpressed, either ubiquitously or 
in cardiomyocytes, demonstrate that FGF2 can promote cardiomyocyte hypertrophy only in times of 
cardiac stress, as FGF2-overexpressing transgenic mice do not experience spontaneous hypertrophy or 
changes in vascular density [77, 85, 97]. Additionally, overexpression of FGF2 results in proliferation of 
both endothelial cells and fibroblasts following injury to the heart, but not under baseline conditions, as 
FGF2-transgenic mice do not have excess extracellular matrix production or vascular formations [97]. 
However, following MI or ex vivo ischemia-reperfusion, FGF2-overexpressing mice show decreased 
infarct size and improved cardiac function [77, 97].  
56 
 
In this study, we aimed to understand the mechanisms governing FGF signaling in the 
development of cardiac hypertrophy and why FGF2 overexpression is not sufficient to induce hypertrophy 
under homeostatic conditions.  We hypothesized that adult cardiomyocytes are not competent to respond 
to an FGF signal, that the FGF signaling pathway is repressed in cardiomyocytes under baseline 
conditions, and that this repression is relieved following injury or stress to the heart.  
To directly test this model, we engineered a transgenic mouse line in which we could cell-
autonomously induce expression of a ligand-independent constitutively-active FGF receptor (caFGFR1-
myc) specifically in cardiomyocytes through doxycycline administration to MHC-rtTA, TRE-caFgfr1-myc 
double transgenic mice (DTG, Figure 1A). We found that in vivo induction of caFGFR1 in adult 
cardiomyocytes leads to rapid changes in cardiomyocyte contractile dynamics and a dynamic obstruction 
in the proximal left ventricle.  This acute pathology is followed by the progressive development of 
concentric hypertrophy with significantly increased cardiac mass and cardiomyocyte size, interstitial 
fibrosis, and myocyte disarray characteristic of hypertrophic cardiomyopathy.  Interestingly, systolic 
function is preserved, even after six months of transgene induction. Examination of signaling pathways 
strongly suggests a mechanism in which activation of FGF signaling in cardiomyocytes leads to both an 
increase in myofilament calcium sensitivity and a reduction in calcium recycling into the sarcoplasmic 
reticulum.  Calcium dysregulation and alterations and myofilament calcium sensitivity are common 
mechanisms implicated in the pathogenesis of familial hypertrophic cardiomyopathy, and as a result, this 
novel model of caFGFR1-induced HCM may be useful for further investigation into the mechanisms 
involved in HCM development and studies aimed at its reversal. 
 
B. Results 
 Doxycycline-inducible cardiomyocyte-specific constitutively-active FGF receptor 1 mouse 
model.  To investigate the potential function of FGF signaling in adult cardiomyocytes, we utilized the 
doxycycline-regulatable TET-on system with the αMHC-rtTA mouse line.  Expression of the reverse 
tetracycline transcriptional activator (rtTA) from the αMHC promoter leads to cardiomyocyte-specific 
expression of the rtTA protein [144].  To determine the effects of cell autonomous activation of FGF 
signaling, we generated a tetracycline response element (TRE)-drivable FGFR31c(R248C)-c-myc 
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transgene, in which FGFR31c(R248C) is a chimeric receptor consisting of the FGFR3c(R248C) mutant 
extracellular and transmembrane domains fused to the FGFR1 tyrosine kinase domain (Figure 3.1A).  
The FGFR3c(R248C) mutation confers ligand-independent constitutive activity [168].  By fusing this 
mutant FGFR3c receptor to the FGFR1 tyrosine kinase domain, one can produce a receptor that 
constitutively activates FGFR1 signaling in the absence of ligand (caFGFR1). A c-myc tag was placed at 
the C-terminal tail of caFGFR1 to allow detection of mutant receptor expression.  Addition of this epitope 
did not affect the activity of the mutant receptor (data not shown).  For simplicity the Tre-Fgfr31c(R248C)-
c-myc transgene will be referred to as Tre-caFgfr1. 
 αMHC-rtTA/TRE-caFGFR1 double transgenic mice (DTG) were examined expression of the c-
myc tag (transgenic caFGFR1 expression only) and FGFR1 (both transgenic caFGFR1 and native 
FGFR1 expression) in the absence of doxycycline to determine the basal level of transgene activation in 
our genetic system, as well as the level of native FGFR1 protein expression in the adult mouse heart.  
Double transgenic animals displayed very low levels of c-myc and FGFR1 protein expression (Figure 1G, 
DTG 0d), while single transgenic TRE-caFGFR1 animals did not show any expression of the transgene or 
native FGFR1 (Figure 3.1B, control 0d).  To determine if this level of basal transgene expression led to a 
cardiac phenotype, we measured the ratio of biventricular weight and total body weight (HW/BW ratio, 
Figure 3.1C), as well as mean cardiomyocyte cross-sectional area (Figure 3.1D) and in vivo left ventricle 
(LV) diastolic posterior wall thickness (LVPWd, Figure 3.1E) and proximal LV peak outflow velocity (LV 
POV, Figure 3.1F) in 12- to 14-week-old mice.  Cardiac mass, myocyte size, and LV wall thickness were 
comparable between double transgenic mice and littermate controls, while a small, but significant, 
increase was observed in peak outflow velocity (1.01 ± 0.61 m/s vs. 0.57 ± 0.18 m/s, p=0.0002).   
 To further investigate whether a pathologic cardiac phenotype was present at baseline, we 
utilized quantitative RT-PCR to examine the gene expression of established markers heart failure, 
hypertrophy, and fibrosis (Figure 3.1G) [9-11, 79].  While the expression of b-type natriuretic peptide 
(bnp) was slightly elevated (2.1 ± 1.2-fold vs. control, not significant), levels of atrial natriuretic peptide 
(anp), beta-myosin heavy chain (mhc), and collagens 1 and 3 (col1a1, col3a1) were unchanged in 
double transgenic hearts at baseline. In all studies, littermate controls included single transgenic mice 
(αMHC-rtTA only, TRE-caFGFR1 only) or wild-type mice.  No significant differences were observed 
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between the three control genotypes in any of the analyzed parameters, and as a result, control data 
were pooled. 
 To test whether αMHC-rtTA can confer inducible expression of caFGFR1 in the heart, we 
examined c-myc and FGFR1 expression following the administration of doxycycline (DOX) chow (Figure 
3.2A).  One day of DOX was sufficient to induce robust expression of the transgene (Figure 3.2A, DTG 
1d), which was maintained at consistent levels with chronic feeding of DOX chow (Figure 3.2A, DTG 7d, 
21d, 168d).  No transgene activation or native FGFR1 expression was visible in littermate control animals 
(Figure 3.2A, control 1d, 7d, 21d, 168d).  We also utilized quantitative RT-PCR to measure the fold 
change in Fgfr1 gene expression (Figure 3.2B).  While Fgfr1 mRNA expression was significantly 
increased at baseline (0d) in double transgenic mice (19.6 ± 6.6-fold vs. control, p=0.001), expression 
increased dramatically after one day on DOX chow (199.2 ± 79.5-fold vs. control, p<0.001) and was 
maintained at these high levels with chronic DOX feeding.  Additionally, we monitored gene expression of 
the ETS transcription factors Etv4 and Etv5 (Figure 3.2C), which have been shown to be activated by 
FGF signaling [15, 169].  Despite the increased Fgfr1 expression, Etv5 and Etv4 gene expression 
remained unchanged at baseline (0d) in double transgenic mice compared to littermate controls.  
Expression of both transcription factors increased significantly after one day of transgene induction (Etv5: 
2.98 ± 0.89-fold vs. control, p<0.001; Etv4: 2.63 ± 1.06 vs. control, p<0.01), and they remained elevated 
with chronic expression of caFGFR1.  Fold change and statistical analysis depicted in Figures 3.2B and 
3.2C was calculated compared to corresponding time-matched littermate controls (not shown for 
simplicity). 
 In vivo characterization of phenotype development in αMHC-rtTA, TRE-caFGFR1 mice.  To 
determine the effect of activating FGF signaling specifically in cardiomyocytes, 12- to 14-week-old double 
transgenic animals and littermate controls were fed doxycycline (DOX)-containing chow for varying 
lengths of time to induce transgene expression, and cardiac function was monitored over time with 
echocardiography.  LV diastolic posterior wall thickness was significantly elevated in double transgenic 
mice within one day of DOX induction (0.99 ± 0.20 vs. 0.88 ± 0.02 mm, p=0.001, LVPWd) (Figure 3.3A), 
and LV mass index was significantly elevated by one week of induction (5.3 ± 1.0 vs. 4.2 ± 0.5, p=0.02, 
LVMI) (Figure 3.3C).  Both parameters continued to increase throughout six months of induction.  
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Meanwhile, LV internal diastolic diameter was significantly decreased within one week of transgene 
induction (3.04 ± 0.26 vs. 3.47 ± 0.21 mm, p=0.001, LVIDd) (Figure 3.3B) and remained relatively 
constant throughout the length of the study.  Systolic function, as measured by ejection fraction (not 
shown) or fractional shortening (Figure 3.3D) remained comparable between double transgenic animals 
and littermate controls throughout the length of the study, and was even significantly increased at three 
time points (1d, 42d, 126d).  Heart rates were slightly, but not significantly, decreased at all time points in 
double transgenic mice (data not shown).  Representative diastolic mid-ventricle short-axis still images 
from double transgenic animals are presented in Figure 3.3E.  Note the concentric and symmetrical 
increase in wall thickness and the decreased chamber volume.   
 To determine the effects of caFGFR1 on the relaxation and contractile properties of the adult 
heart, we performed in vivo hemodynamic analysis after one day (Figure 3.4A, Table 3.1) and six weeks 
(Figure 3.4B, Table 3.1) of transgene induction.  Following one day of induction, no significant differences 
were observed in heart rate, dPmax, dPmin, end systolic or diastolic pressure (ESP, EDP), or tau (Glantz) 
values of relaxation (Table 3.1).  However, end systolic volume was greatly reduced (18.2 ± 3.3 vs. 31.7 ± 
4.5 mL, p=0.051), and end diastolic volume was significantly decreased in double transgenic mice 
compared to littermate controls (31.8 ± 2.8 vs. 51.2 ± 4.5 mL, p=0.01).  In order to more accurately 
assess the contractility and stiffness of the ventricle, we increased the afterload of the heart by briefly 
constricting the transverse aorta and examining the end-systolic pressure-volume relationship (ESPVR) 
between the baseline and increased afterload pressure-volume (PV) loops.  The slope of the ESPVR is 
an excellent indicator of the contractility of the heart, and it is clearly elevated following 24 hours of 
caFGFR1 induction (10.4 ± 1.6 vs. 3.6 ± 1.1, p=0.004, Figure 3.4A). 
 Six weeks of transgene induction resulted in an obstructive phenotype, as indicated by the altered 
appearance of the pressure and dP/dt tracings (Figure 3.4B) and the significantly elevated end systolic 
pressures seen in double transgenic animals compared to littermate controls (191.6 ± 21.2 vs. 105.8 ± 2.7 
mmHg, p=0.01, Figure 3.4B).  Additionally, there was a significant increase in tau (Glantz) in double 
transgenic hearts (Table 3.2), suggesting the presence of a relaxation defect.  Due to the dynamic 
obstruction, the shape of the PV loop of the double transgenic mice was significantly altered, making it 
difficult to directly compare other parameters to littermate controls. 
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 Echocardiographic Doppler analysis supported the findings from the hemodynamic studies.  
Representative color Doppler images from double transgenic mice (Figure 3.4C, bottom) showed a very 
distinctive point of flow convergence (Venturi effect) in the mid- to proximal-LV that was never seen in 
control mice (Figure 3.4C, top).  Doppler tracings revealed significantly elevated outflow velocities at the 
point of the flow convergence (Figure 3.4D), which, when quantified, were more than four times higher 
than control values (>3.0 vs. <1.0 m/s, p<0.001 at all time points, Figure 3.4E).  As stated previously and 
shown in Figure 3.1F, double transgenic mice also showed significantly elevated proximal-LV outflow 
velocities at baseline; however, these values were significantly lower than velocities seen after 24 hours 
of transgene induction (0d: 1.01 ± 0.61 vs. 1d: 2.98 ± 0.80 m/s, p<0.001), and did not affect phenotype 
development.  However, where possible, mice with peak outflow velocities greater than 1.0 m/s at 
baseline were not utilized for further analysis. 
 Histologic characterization of phenotype and pathological gene expression analysis.  To 
further characterize the hypertrophy phenotype in double transgenic mice, we performed gross and 
histological analysis of hearts from double transgenic and littermate control mice.  Following 42 days of 
caFGFR1 induction, hearts were visibly larger in double transgenic animals (Figure 3.5A).  This difference 
was even more apparent after 300 days of transgene expression, as demonstrated in Trichrome-stained 
cardiac cross-sections from control (Figure 3.5B, top) and double transgenic hearts (Figure 3.5B, bottom).  
Also note that even after ten months of caFGFR1 expression, concentric hypertrophy was still present, 
and none of the six hearts examined showed signs of progressing to a dilated state.  Histologic analysis 
of LV cross-sections induced with DOX for 42 days showed patchy areas of myocyte disarray (H&E 
staining, Figure 3.5C) and increased interstitial fibrosis (Picrosirius red staining, Figure 3.5D).  
Fluorescein-tagged wheat germ agglutinin (FITC-WGA) was utilized to label all cell membranes in 
sections of the adult heart.  Following six months of transgene induction, FITC-WGA staining clearly 
illuminated large patches of increased interstitial cells, which were never seen in littermate controls 
(Figure 3.5E).  FITC-WGA staining from representative double transgenic mice, shown in Figure 3.5F, 
illustrates the progressive enlargement of myocytes (cut in cross section) from baseline (0d) to six months 
(168d) of transgene induction.  Cardiomyocyte cross-sectional area was significantly increased by one 
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week of caFGFR1 induction (287.8 ± 15.4 vs. 229.2 ± 31.5 µm
2
, p=0.002) and continued to increase 
through six months of induction (512.0 ± 152.2 vs. 271.3 ± 30.1 µm
2
, p=0.02, Figure 3.5G).   
 To confirm that the hypertrophy seen in double transgenic mice was pathologic, quantitative RT-
PCR was used to examined the expression of markers of pathological ventricular remodeling (Figure 
3.5H & I).  The antihypertrophic and antifibrotic natriuretic peptides, Anp and Bnp, were significantly 
elevated in double transgenic mice after one day of caFGFR1 induction (Anp: 3.2 ± 1.7-fold vs. control, 
p=0.01; Bnp: 7.7 ± 4.2-fold vs. control, p=0.003), while the fetal hypertrophy marker β-myosin heavy chain 
and the fibrotic markers collagens 1 and 3 were not significantly elevated until 42 days of transgene 
induction (MHC: 7.9 ± 5.2-fold vs. control, p=0.02; Col1a1: 1.5 ± 0.4-fold vs. control, p=0.04; Col3a1: 4.4 
± 2.3-fold vs. control, p=0.01). 
Exercise tolerance.  Double transgenic mice expressing caFGFR1 exhibited all of the 
pathophysiological characteristics of hypertrophic cardiomyopathy (HCM).  Because one of the most 
common clinical manifestations of HCM is exercise intolerance [170], it was important to determine if 
chronic induction of caFGFR1 and the resulting concentric hypertrophy would result in impair 
performance during forced exercise.  Adult mice were fed DOX chow for six months and then subjected to 
an acute treadmill stress test, where their exercise tolerance was measured by the length of time they 
were able to run unassisted (time to failure).  Interestingly, double transgenic mice with chronic caFGFR1 
expression did not display any signs of exercise intolerance and were capable of running for the same 
length of time as their littermate controls (24.4 ± 1.0 vs. 21.5 ± 4.7 minutes, not significant, Figure 3.6). 
 Reversibility of phenotype.  One of the advantages of the Tet-on system is its reversibility.  Just 
as addition of DOX leads to the translocation of the rtTA to the nucleus and the binding to the TRE, the 
removal of DOX inactivates the rtTA and halts transcription of the transgene.  To assess the reversibility 
of the caFGFR1-induced phenotype, 12- to 14-week old αMHC-rtTA, TRE-caFGFR1 mice and littermate 
controls were induced with DOX chow for six weeks and fed normal chow for six weeks.  Development 
and reversal of hypertrophy was evaluated using in vivo echocardiography and postmortem histological 
and protein or gene expression analysis.  LV mass index (LVMI, Figure 3.7C) was significantly reduced 
by 16.5% from the LVMI observed following six weeks on DOX chow (5.48 ± 0.72 vs. 6.57 ± 0.85 mg/g, 
p=0.007), although it remained slightly elevated compared to control mice after six weeks off DOX (5.48 ± 
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0.72 vs. 4.60 ± 0.51 mg/g, not significant).  Similarly, LV internal diastolic diameter (LVIDd, Figure 3.7B) 
was significantly increased by 12% from the LVIDd observed before DOX removal (3.44 ± 0.21 vs. 3.07 ± 
0.11 mm, p=0.01), and it returned to near control levels following DOX removal (3.44 ± 0.21 vs. 3.61 ± 
0.38 mm, not significant).  LV diastolic posterior wall thickness (LVPWd, Figure 3.7A) was also reduced 
by 16% from the wall thickness observed after six weeks on DOX (1.14 ± 0.16 vs. 1.36 ± 0.25 mm, 
p=0.007), but remained significantly elevated over littermate controls after six weeks off DOX (1.14 ± 0.16 
vs. 0.85 ± 0.09 mm, p=0.01).  LV peak outflow velocity (LV POV, Figure 3.7D), measured at the point of 
flow convergence in the mid-ventricle, was the most resistant to reversal.  While outflow velocity was 
significantly decreased by 20% following removal of DOX (3.17 ± 0.58 vs. 3.99 ± 0.0 m/s, p=0.02), it 
remained significantly elevated compared to littermate controls (3.17 ± 0.58 vs. 0.66 ± 0.20 m/s, 
p<0.001).  Consistent with the in vivo wall thickness, mean cardiomyocyte cross-sectional area remained 
significantly larger than littermate controls following DOX removal for six weeks (332 ± 21 vs. 233 ± 32 
µm
2
, p=0.005; Figure 3.7E), despite decreasing by 24% compared to pooled data from two independent 
cohorts of double transgenic mice induced for six weeks (332 ± 21 vs. 435 ± 102 µm
2
, n=4 and 7, 
p=0.08).   
To determine whether the continued presence of phenotype was the result of resistance to 
reversibility or continued expression of caFGFR1, Western blot analysis of c-myc expression (Figure 
3.7F) and quantitative RT-PCR analysis for Fgfr1 gene expression (Figure 3.7G) were performed. The 
transgene, as measured by its c-myc tag, was still expressed at relatively high levels after 42 days of 
DOX removal (DTG 42d ON, 42d OFF; Figure 3.7F), although expression was significantly reduced 
compared to transgene expression following three weeks of DOX induction (DTG 21d; Figure 3.7F).  As 
expected, no transgene expression was observed in littermate control animals (Control 21d; Figure 3.7F).  
This continued expression of the c-myc tag following DOX removal corresponded to a 54 ± 13-fold 
increase of Fgfr1 compared to littermate controls (p=0.0002), down 82% from the 299 ± 60-fold seen 
following transgene induction for 42 days.  Despite continued transgene expression, levels of expression 
of downstream mediators of FGF signaling, Etv5 and Etv4 (Figure 3.7H), and markers of pathological 
ventricular remodeling (Figure 3.7I) returned to normal levels following 42 days off DOX. 
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 Mechanisms involved in phenotype development following induction of caFGFR1.  FGF 
receptors can activate a variety of pathways, including MAPK/ERK, PI3K/Akt, PLCγ, and STATs.  In an 
effort to elucidate the mechanisms involved in the development of the hypercontractility and hypertrophy 
seen in double transgenic mice, we analyzed protein expression throughout the time course of caFGFR1 
induction.  While there was a trend towards transient 2-fold increase in ERK1/2 activation after one day of 
induction, this change was not consistent enough to achieve significance (nDTG=8, ncontrol=5; Figure 3.8), 
and no changes were apparent beyond 24 hours of caFGFR1 induction.  We also examined the activation 
of other MAPKs (p38, JNK), as well as Akt, PLC, and STATs (Stat3, Stat5), none of which showed any 
trends toward activation following induction of FGF signaling in cardiomyocytes (Figure 3.8).  Additionally, 
pharmacologic inhibitors of MEK1/2 (U0126), PI3K (Wortmannin), and Calcineurin (Cyclosporine A) were 
tested in vivo and none were able to inhibit phenotype development (Table 3.3). 
 Because there was no clear activation of a pathway, or pathways, directly downstream of the 
FGF receptor (despite increased expression of Etv4 and Etv5), we examined other signaling pathways 
that could result in hypertrophy or hypercontractility.  We hypothesized that induction of caFGFR1 could 
lead to increased sensitization of cardiomyocytes to sympathetic signaling, since adrenergic activation in 
the heart has been shown to both increase contractility and cause hypertrophy in cardiomyocytes [171].  
As a result, we examined the phosphorylation of targets downstream of adrenergic receptors, such as 
protein kinase A (PKA), troponin I (TnI), and phospholamban.  No changes in activation of PKA at any 
time during caFGFR1 induction were observed.  However, in contrast to what we would expect if 
adrenergic signaling were increased, phosphorylation of TnI was significantly decreased by one week of 
transgene expression (0.26 ± 0.21 vs. control, p=0.01, Figure 3.9).  There was also a trend towards 
decreased phosphorylation of phospholamban, but this result was much more variable than TnI 
phosphorylation (data not shown).  In addition to increased adrenergic signaling, alterations in calcium 
handling are a common mechanism in the development of hypertrophy [5, 6].  Western blot analysis 
revealed significant downregulation of Serca2, the calcium ATPase that recycles calcium back into the 
sarcoplasmic reticulum, by seven days of transgene induction (0.40 ± 0.24 vs. control, p=0.03, Figure 
3.9).   
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Assessment of cardiomyocyte contractile properties.  To determine whether changes in 
cardiac contractility seen in vivo were due to cell autonomous effects on the cardiomyocyte, 10- to 12-
week-old double transgenic and littermate control mice were induced with doxycycline for 24-48 hours, 
and then unloaded cell shortening was assessed in freshly isolated ventricular myocytes paced at 0.5 Hz.  
Representative traces of myocyte contraction (Figure 3.10A) and quantitation of myocyte length 
demonstrate that myocytes isolated from double transgenic hearts had significantly shorter sarcomeric 
lengths at both diastole and systole (Figure 3.10B), with an overall increase in fractional shortening 
(Figure 3.10C) compared to myocytes from littermate controls, suggesting that caFGFR1 leads to both 
impaired relaxation and enhanced contraction in cardiomyocytes. 
To determine if the failure to fully relax was due to inherent changes in sarcomeric proteins, 2,3-
butanedione monoxime (BDM), which inhibits actin-myosin interactions and slows cross bridge cycling 
[172, 173],  was added to isolated ventricular myocytes, and led to significant lengthening of both control 
and double transgenic sarcomeres (Figure 3.10D).  More importantly, myocytes from double transgenic 
mice experienced a significantly greater change in sarcomere length and approached the same final 
relaxed sarcomere length as their littermate controls following BDM addition (Figure 3.10E). 
To determine if the altered contractile properties in double transgenic myocytes were the result of 
increased intracellular calcium concentration (due to decreased calcium recycling), myocytes were loaded 
with BAPTA-AM, an intracellular calcium chelator [173].  In contrast to BDM, there was no change in final 
relaxed sarcomere length in either control or double transgenic myocytes, suggesting that increased 
intracellular calcium is likely not involved in the altered relaxation of double transgenic cardiomyocytes 
(data not shown). 
Clinical usefulness.  Two classes of drugs that have been proven to reverse pathological 
remodeling and improve cardiac function in heart failure are angiotensin receptor blockers, such as 
losartan, and beta-blockers, such as propranolol [174].  While the precise mechanisms by which beta-
blockers improve cardiac function and promote reverse remodeling are unknown, this treatment is one of 
the mainstays for the symptomatic relief of obstructive HCM due to its ability to decrease the outflow 
gradient [174, 175].  Meanwhile, losartan is contraindicated in patients with LV outflow obstruction due to 
its effect on blood pressure (which can increase outflow gradient) [176], but recent studies have indicated 
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that blockade of angiotensin signaling can prevent much of the pathological remodeling in animal models 
of HCM [177]. 
To examine the clinical usefulness of this new model of hypertrophic cardiomyopathy, double 
transgenic mice were given losartan (80 mg/kg/d) or propranolol (67 mg/kg/d) in their drinking water in an 
attempt to determine if these drugs could prevent or lessen phenotype development (Table 3.4).  
Treatment began one week prior to the start of DOX chow, and continued throughout one week of 
transgene induction.  Both drugs significantly abrogated the hypertrophic response seen in untreated 
DTG mice (induced for one week, DTG 7d), as assessed by in vivo LV mass index (losartan DTG: 4.3 ± 
0.6 mg/g, propranolol DTG: 4.0 ± 0.7 mg/g, DTG 7d: 5.3 ± 1.0, DTG 0d: 4.0 ± 0.4 mg/g).  The increase in 
LV posterior wall thickness was also moderately blocked with both drugs, though neither treatment 
caused a significant reduction (losartan DTG: 0.97 ± 0.06 mm, propranolol DTG: 0.95 ± 0.16 mm, DTG 
7d: 1.14 ± 0.27 mm, DTG 0d: 0.85 ± 0.09 mm).  Only propranolol significantly reduced the LV outflow 
velocity, though it was still significantly elevated compared to measurements taken prior to drug treatment 
and caFGFR1 induction (DTG 0d) (losartan DTG: 4.8 ± 0.2 m/s, propranolol DTG: 2.3 ± 1.2 m/s, DTG 7d: 
4.1 ± 0.8, DTG 0d: 0.9 ± 0.4).  These studies suggest that this model of caFGFR1-induced HCM may 
prove useful to evaluate other treatments aimed at preventing or reversing the course of this pathological 
condition. 
 
C. Discussion 
  Induction of caFGFR1 in adult cardiomyocytes results in hypercontractility and a 
hypertrophic cardiomyopathy.  In this study, we created a new mouse model in which we could induce 
FGF receptor signaling specifically in cardiomyocytes in an attempt to better understand the relationship 
between FGF signaling and the development of hypertrophy.  We hypothesized that adult cardiomyocytes 
are not competent to respond to an FGF signal due to repression of the FGF signaling pathway under 
homeostatic conditions.  However, we discovered that cell autonomous activation of FGF signaling, via a 
constitutively active FGF receptor, is sufficient to induce significant hypertrophy within seven days of 
transgene expression (Figures 3.3 and 3.5).  This hypertrophy is concentric, leading to significantly 
increased wall thickness (Figure 3.3A) and reduced chamber volume (Figure 3.3B).  Cardiac mass 
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(Figure 3.3C) and cardiomyocyte cross sectional area (Figure 3.5C) progressively increased throughout 
six months of caFGFR1 induction (illustrated in Figures 3.3E and 3.3F).  Patchy areas of fibrosis, elevated 
expression of pathologic cardiac markers, and particularly myocyte disarray (Figure 3.5) and maintenance 
or enhancement of systolic function (Figure 3.3D) support the notion that sustained activation of FGF 
signaling in adult cardiomyocytes leads to a hypertrophic cardiomyopathy. 
In addition to the development of HCM, we discovered that inducing caFGFR1 can rapidly 
increase the contractility of the heart within 24 hours of exposure to DOX, as evidenced by the 
significantly elevated slope of the end-systolic pressure-volume relationship curve following an increase in 
the afterload of the heart (Figure 3.4A).  This hypercontractility results in the narrowing of the ventricle 
during systole, leading to a high velocity jet of blood flowing past the papillary muscles in the mid- to 
proximal-ventricle (Figure 3.4C-E).  This effect is further amplified to the point of a dynamic obstruction 
following the development of concentric hypertrophy, as evidenced by the significant elevation in end 
systolic pressure in the distal ventricle (Figure 3B).  The hypercontractility phenotype is also extremely 
sensitive to activation of FGF signaling, as it is significantly elevated even at baseline due to a small 
amount of leakiness and minimal transgene expression in double transgenic mice (Figure 3.1B, DTG 0d).  
It is also resistant to reversal following removal of DOX (Figure 3.7D).  Hypertrophic parameters 
approached near control levels after six weeks off DOX, while peak outflow velocity in the mid-ventricle 
remained significantly elevated compared to littermate controls.  The fact that double transgenic mice at 
baseline do not show signs of hypertrophy despite having increased contractility suggests that a low level 
of activated FGFR1 in cardiomyocytes directly regulates cardiac contractility, while prolonged exposure to 
high levels of activated FGFR1 leads to the development of HCM.  These data, showing a rapid and 
significant increase in myocyte contractility in response to FGF pathway activation, reveal at least one 
component of potential cardioprotection by FGF following myocardial injury. 
Constitutively-active FGFR1 in cardiomyocytes alters mechanisms common to HCM 
pathophysiology.  Hypertrophic cardiomyopathy affects roughly one out of 500 adults and is the most 
common cardiovascular genetic disorder.  The majority of cases (45-70%) can be attributed to one of 
many possible dominant mutations in sarcomeric proteins (over 800 mutations in 11 different contractile 
genes [6].  However, a fairly large number of patients develop HCM and lack one of these known 
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mutations.  In addition, this is a complex and heterogeneous disease, and the correlations between 
genotype and phenotype remain poorly understood.  To our knowledge, no study has shown that 
overactivation of FGFR1 is linked to HCM.  However, mutations that lead to increased Ras activity, a 
known mediator of the FGF signaling cascade, are associated with the development of HCM (as well as a 
host of other cardiac and syndromic defects) [116].   In an effort to determine the mechanisms that lead to 
hypercontractility and the development of HCM in our mouse model, we examined pathways known to be 
activated by FGF receptor tyrosine kinases.  While there were some trends (transient activation of 
ERK1/2 after one day of induction, decreased Akt activation), activation of downstream pathways 
(ERK1/2, p38, JNK, Akt, PLCg1, Stat3, Stat5) tended to be inconsistent and thus inconclusive in both 
double transgenic hearts and controls.  However, the downstream FGF-responsive target genes Etv4 and 
Etv5, were consistently and persistently increased.  Given the lack of clear activation of one particular 
pathway, or pathways, it does not appear that these classical downstream signaling pathways are directly 
involved in the development of hypercontractility or progression of hypertrophy seen in this model.  
Similar to our findings, there was no increase in phosphorylated ERK or Akt in a Ras-induced HCM 
mouse model [178], suggesting that a novel or nonclassical pathway was responsible for development of 
the HCM phenotype.  
As a result, we turned our attention to other possible mechanisms for the development of 
hypercontractility and HCM, and hypothesized that expression of caFGFR1 resulted in cardiomyocytes 
that were hypersensitive to sympathetic stimulation. Norepinephrine or epinephrine bind to beta-
adrenergic receptors (G-protein coupled receptors) on cardiomyocytes, leading to synthesis of cAMP and 
activation of protein kinase A (PKA), which phosphorylates a variety of downstream targets, including 
myofilament proteins (such as troponin I and myosin binding protein C), ion channels, and proteins 
involved in calcium handling (phospholamban).  Phosphorylation of these targets leads to increased 
inotropy (contractility) and increased lusitropy (relaxation) in cardiomyocytes [171].  However, caFGFR1-
expressing hearts showed no increase in PKA activation, and significantly decreased phosphorylation of 
troponin I (TnI) by one week of DOX induction, suggesting that sympathetic hypersensitization was not 
the mechanism for the increased contractility.  
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However, decreased TnI phosphorylation has important implications for the mechanism of 
phenotype development in these mice. TnI is a regulatory protein in the sarcomere that plays a key role in 
cardiomyocyte contraction and relaxation.  TnI inhibits the interaction between actin and myosin during 
diastole, when cytosolic calcium concentration is low.  During systole, calcium concentration rises, binds 
to troponin C (TnC) and leads to a conformational change in the troponin complex that removes TnI 
inhibition of cross bridge formation and promotes sarcomere contraction.  Phosphorylation of TnI by 
protein kinase A or C (PKA, PKC) represents an important regulatory mechanism to modulate the 
contractile properties of the myofilament, as it increases the amount of calcium necessary for activation of 
contraction (i.e., it decreases the calcium sensitivity of the sarcomere) and increases the rate of calcium 
dissociation [179, 180].  This ultimately results in accelerated relaxation and increased crossbridge 
cycling.  Therefore, the decrease in TnI phosphorylation seen in this model would result in increased 
calcium sensitivity of the sarcomere, leading to contraction at lower calcium concentrations, and ultimately 
to impaired relaxation.  Mechanisms governing the dephosphorylation process are much less clear, 
although it has been demonstrated that protein phosphatases 1 or 2A (PP1, PP2A) are capable of 
dephosphorylating TnI [180-184].  Importantly, activation of PP2A has been implicated as a feedback 
mechanism downstream of FGF receptor activation [185-187], making this one possible mechanism by 
which caFGFR1 could have direct effects on myofilament physiology.  The potential involvement of 
protein phosphatases in the pathology of hypertrophic cardiomyopathy was further implicated in a study 
utilizing a transgenic mouse model of activated Ras, a small G-protein downstream of the FGF receptor 
[178].  Regardless of the specific mechanism, decreased phosphorylation of TnI and the resulting 
increased myofilament calcium sensitivity provides a common link between this caFGFR1 expression 
model of HCM and classical models involving sarcomere mutations.  At least 62 mutations have been 
identified in thin filament regulatory proteins (tropomyosin, troponin T, and troponin I), many of which 
have been shown to increase myofilament calcium binding affinity and one of which prevents PKA-
mediated phosphorylation [188, 189].   
Another proposed model for the development and progression of HCM is abnormal intracellular 
calcium handling [5, 6].  Several studies of mouse models of HCM have demonstrated decreasing levels 
of calcium handling proteins, as well as diminished calcium transients and release of calcium from the 
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sarcoplasmic reticulum [178, 190].  One study even demonstrated that administration of diltiazem, an L-
type calcium channel blocker, before the emergence of hypertrophy was sufficient to maintain normal 
levels of calcium handling proteins and prevent phenotype development [190].  As a result, we examined 
the expression levels of various calcium handling proteins, and found that Serca2, the calcium ATPase 
responsible for recycling calcium back into the sarcoplasmic reticulum, was significantly reduced following  
induction of caFGFR1 for one week (Figure 3.9). Downregulation of Serca2 would be expected to result in 
decreased sarcoplasmic reticulum calcium concentration and potentially higher cytosolic calcium 
concentration, leading to both stronger sarcomere contraction as well as an inability to relax. 
In an attempt to further characterize the mechanisms involved in the development of 
hypercontractility and HCM in our genetic model, we examined the contractility of isolated cardiomyocytes 
from double transgenic and littermate control mice induced with DOX for 24-48 hours.  Baseline 
recordings revealed that double transgenic myocytes were significantly shorter during diastole than 
control myocytes, suggesting the presence of a relaxation defect.  Double transgenic myocytes also had 
significantly increased contractility (fractional shortening), suggesting that caFGFR1 leads to intrinsic 
changes in cardiomyocyte contractile properties.  To define the relative contribution of cytosolic calcium 
versus changes in myofilament contractile properties, we then subjected these myocytes from DOX-
induced double transgenic and littermate controls to 2,3-Butanedione monoxime (BDM), an inhibitor of 
myosin-actin interactions, or BAPTA-AM, a membrane-permeable calcium chelator.  BDM was able to 
significantly increase diastolic sarcomere length in both control and DTG myocytes.  While DTG myocytes 
experienced a greater overall change in sarcomere length, they remained significantly shorter than 
control myocytes, indicating a partial reversal of the relaxation defect.  BAPTA-AM, however, had little 
effect on sarcomere length in control or DTG myocytes.  These data strongly suggest that alterations in 
cardiomyocyte contractility (specifically relaxation) that result from expression of caFGFR1 are due to 
changes within the myofilament and not from a rise in cytosolic calcium concentration.  Further studies 
are necessary to determine precisely how FGF signaling affects myofilament physiology.  While it is likely 
that decreased TnI phosphorylation plays a role in the pathophysiology of our model, we did not observe 
significant changes in p-TnI until seven days of transgene induction, suggesting that other modifications 
to the contractile apparatus may occur earlier.   
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 In conclusion, the doxycycline-inducible cardiomyocyte-specific caFGFR1 mouse provides a 
unique model of HCM that can be utilized to examine the common pathways that lead to phenotype 
development, as well as the extent of phenotype prevention and/or reversibility.  This model also 
suggests the possibility that activating mutations in FGFR1 may directly lead to HCM or may modify the 
phenotype when combined with mutations in other proteins.  Finally, perhaps the most striking finding 
from these studies is that low levels of activated FGFR1 have rapid and potent effects on cardiac 
contractility without any pathological effects, suggesting that targeted activation of the FGF signaling 
pathway may be beneficial to patients with heart failure and poor systolic function.  Further investigation is 
necessary to more precisely elucidate the mechanisms responsible for the increased contractility 
following expression of caFGFR1, as well as pathways involved in the rapid progression from 
hypercontractility to HCM. 
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Figure 3.1 Inducible constitutively-active FGFR1 genetic system shows minimal baseline activity. 
(A) We generated a tetracycline response element (TRE)-drivable FGFR31c(R248C)-c-myc transgene, in 
which FGFR31c(R248C) is a chimeric receptor consisting of the FGFR3c(R248C) mutant extracellular 
and transmembrane domains (which confer ligand-independent constitutive activity) fused to the FGFR1 
tyrosine kinase domain. (B) Western blot demonstrating minimal expression of c-myc tag and FGFR1 in 
double transgenic animals (DTG) not exposed to DOX (0d).  No transgene or FGFR1 expression is visible 
in single transgenic controls (TRE). -tubulin expression demonstrates equal protein loading.  (C-E) 
Twelve- to 14-week-old mice show no evidence of hypertrophy on gross measurement of biventricular 
weight/body weight ratio (HW/BW, C; nDTG=7, ncontrol=7), histological measurement of mean 
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cardiomyocyte cross sectional area (CM CSA, D; nDTG=5, ncontrol=5), or echocardiographic measurement 
of diastolic left ventricular posterior wall thickness (LVPWd, E; nDTG=47, ncontrol=23). No differences were 
observed between littermate controls (αMHC-rtTA only, TRE-caFGFR1 only, or wild-type), so results were 
pooled for analysis. (F) Minimal expression of caFGFR1 is sufficient to induce a small, but significant, 
increase in outflow velocity from the proximal LV.  (G) Quantitative RT-PCR analysis showing no 
significant changes in markers of pathologic cardiac remodeling (n=4 for DTG and controls). Error bars = 
standard deviation.  + p<0.001. 
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Figure 3.2 Constitutively-active FGFR1-myc is rapidly inducible with consistently maintained 
levels of expression over time.  (A) Western blots showing expression of FGFR1 and the c-myc tag 
(with -tubulin loading control).  Little to no FGFR1 expression is observed in single transgenic controls.  
A small amount of c-myc and FGFR1 expression is observed in DTG hearts at baseline (0d), and level of 
caFGFR1-myc transgene expression increases dramatically following feeding of DOX chow for as little as 
24 hours (DTG 1d).  Transgene protein expression remains relatively constant with chronic activation 
(DTG 7d, 21d, and 168d).  (B) Quantitative RT-PCR analysis (DTG: n0d=4, n1d=7, n7d=5, n21d=6, n168d=4) 
showing a significant 19-fold increase in Fgfr1 mRNA in uninduced DTG animals (0d) that rises to a 200-
fold increase within one day of transgene induction (1d).  FGFR1 gene expression remains relatively 
constant with chronic DOX chow feeding.  (C) No significant changes in downstream transcription factors 
Etv5 or Etv4 were measured at baseline (0d), but significant and consistent induction was observed after 
one day of feeding DOX chow (1d). Fold change is versus corresponding time-matched littermate controls 
(not shown; n0d=4, n1d=6, n7d=4, n21d=5, n168d=4).  Error bars = standard deviation.  *p<0.05, ** p<0.01, + 
p<0.001.  
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Figure 3.3 Induction of caFGFR1 in adult cardiomyocytes results in the development of concentric 
hypertrophy with preservation of systolic function over time. Twelve- to 14-week-old mice were 
induced with DOX chow for varying lengths of time and cardiac function was monitored using 
echocardiography.  (A) Left ventricular (LV) diastolic posterior wall thickness (LVPWd, A) was significantly 
elevated by one day of induction, while LV mass index was significantly elevated (LVMI, C) and LV 
internal diastolic diameter significantly decreased (LVIDd, B) within seven days of DOX induction. (D) 
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Systolic function was maintained throughout 6 months of transgene induction.  Littermate controls 
represent single transgenic (αMHC-rtTA or TRE-caFGFR1) or wild-type littermates; no genotype-specific 
differences were observed and thus controls were pooled for analysis.  Error bars = standard deviation.  
*p<0.05, **p<0.01, +p<0.001.  0d: nDTG=47, ncontrol=23; 1d: nDTG=8, ncontrol=4; 7d: nDTG=17, ncontrol=7; 42d: 
nDTG=14, ncontrol=12; 84d: nDTG=4, ncontrol=4; 126d: nDTG=4, ncontrol=4; 168d: nDTG=4, ncontrol=4. (E) 
Representative short axis echocardiographic images depicting the progression of hypertrophy in double 
transgenic animals (DTG) from baseline to 168 days (six months) of induction.   
  
76 
 
 
Figure 3.4 In vivo induction of caFGFR1 in adult cardiomyocytes leads to a hypercontractile 
phenotype with the development of a dynamic obstruction in the proximal left ventricle. (A) 
Representative pressure-volume (PV) loops from hemodynamic analysis of double transgenic adult mice 
(DTG) induced with DOX for one day compared to littermate controls (1).  To examine the contractility of 
the heart, afterload was increased by briefly occluding the aorta, causing an increase in the end systolic 
pressure and volume in both cohorts (2).  The slope of the end systolic pressure-volume relationship 
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(ESPVR, dotted line) is significantly elevated in double transgenic mice (n=3 for DTG and control). (B) 
Representative pressure (top) and dP/dt (bottom) tracings indicating significantly elevated end systolic 
pressure (ESP) and the presence of a dynamic obstruction in DTG mice induced with DOX for 42 days 
(nDTG=3, ncontrol=2). (C) Representative color Doppler images (blue = blood outflow, red = blood inflow) 
and (D) proximal LV Doppler tracings illustrating flow convergence characteristic of the Venturi effect 
(yellow arrow) and elevated outflow velocity at the point of obstruction in the proximal LV in DTG mice. (E) 
Quantitation of outflow velocity at the point of flow convergence, indicating that a dynamic obstruction is 
present at baseline in DTG mice, increases significantly with one day of transgene induction, and reaches 
the maximum measurable velocity by seven days of induction. Error bars = standard deviation.  *p<0.05, 
**p<0.01, +p<0.001. 
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Figure 3.5 Chronic induction of caFGFR1 results in a pathologic state with molecular and 
histologic characteristics of hypertrophic cardiomyopathy. (A) Induction of caFGFR1 for 42 days 
results in grossly enlarged hearts in double transgenic (DTG) compared to littermate control mice.  (B) 
Following 300 days of transgene induction, massive DTG hearts show concentric hypertrophy with no 
evidence of progression to dilatation (scale bar = 1mm).  (C-D) Histological examination of DTG hearts 
induced with DOX for 42 days reveals patchy areas of myocyte disarray (H&E, 20x magnification, C) and 
fibrosis (picrosirius red, 20x magnification, D).  (E) Six months (168d) of transgene induction results in 
patchy areas of increased interstitial cells illustrated by FITC-tagged wheat germ agglutinin staining 
(WGA, 40x magnification).  (F) FITC-WGA staining illustrates the progressive enlargement of 
cardiomyocytes in DTG mice following chronic induction with DOX chow (scale bar = 20m).  (G) 
Quantitation of mean cardiomyocyte cross-sectional area (CM CSA) demonstrates that cardiomyocytes 
are significantly larger by one week of transgene induction, with continued growth through six months of 
induction.  (H-I) Quantitative RT-PCR for pathologic markers of LV remodeling reveals significant 
upregulation of the fibrotic markers collagens 1 and 3 (col1a1, col3a1, H) by 42 days of transgene 
induction, with significant upregulation of heart failure markers atrial natriutetic and b-type natriuretic 
peptides (anp, bnp) within one day of caFGFR1 expression and the hypertrophy marker β-myosin heavy 
chain (bmhc) by 42 days of induction with DOX (I)  Fold change is versus corresponding time-matched 
littermate controls (not shown). DTG: n0d=4, n1d=7, n7d=5, n42d=4, n168d=4; controls: n0d=4, n1d=6, n7d=4, 
n42d=5, n168d=4.  Error bars = standard deviation. *p<0.05, **p<0.01. 
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Figure 3.6 Chronic induction of caFGFR1 and significant concentric hypertrophy does not cause 
exercise intolerance in double transgenic mice.  Twelve- to 14-week-old mice were fed DOX chow to 
induce caFGFR1 expression for 168 days (six months), and then subjected to an acute treadmill stress 
test to determine if the presence of severe hypertrophy resulted in exercise intolerance.  Double 
transgenic mice (DTG) were capable of running for the same amount of time as their single transgenic 
littermate controls (nDTG=3, ncontrol=4).  Error bars = standard deviation. 
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Figure 3.7 Transgene induction for 42 days, followed by DOX removal for 42 days leads to partial 
phenotype reversal. Twelve- to 14-week-old mice were fed DOX chow for 42 days to induce the HCM 
phenotype and then DOX was removed and mice were allowed to recover for 42 days. (A-E) Mice were 
monitored using serial screening echocardiograms.  (A) LV diastolic posterior wall thickness (LVPWd) 
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was significantly increased in double transgenic mice (DTG, n=6) compared to littermate controls (n=4) 
following both DOX induction and DOX removal. While wall thickness did decrease slightly after removal 
of DOX, this difference was not significant. (B) LV internal diastolic diameter (LVIDd) was significantly 
decreased compared to controls following 42 days of DOX exposure. Unlike LVPWd, LVIDd returned to 
near control levels after removal of DOX for 42 days. (C) LV mass index (LVMI) was also significantly 
increased in DTG mice compared to littermate controls following 42 days of caFGFR1 induction.  LVMI 
decreased significantly and approached control values following DOX removal.  (D) Despite decreasing 
significantly following removal of DOX, peak outflow velocity (LV POV) from the proximal ventricle was 
still elevated compared to littermate controls.  (E) WGA staining was performed to assess mean 
cardiomyocyte cross-sectional area (CM CSA) at the endpoint of this study.  While myocyte size was 
smaller than that seen following six weeks of caFGFR1 induction, cells were still significantly larger than 
littermate controls.  (F) Western blot analysis showing the significant decrease of transgene expression 
following removal of DOX (DTG 42d ON 42d OFF), compared to transgene expression after three weeks 
of induction (DTG 21d; protein samples from six weeks of induction were unavailable). No transgene 
expression is visible in TRE-caFGFR1-myc single transgenic controls (Control 21d). -tubulin expression 
was used as a loading control. (G-I) Quantitative RT-PCR analysis demonstrates continued 
overexpression of Fgfr1 in double transgenic hearts following 42 days off DOX (gray bar), despite a large 
reduction from the level of expression observed following 42 days on DOX (black bar, G).  Expression of 
downstream mediators of FGF signaling (Etv5, Etv4, H) and markers of pathologic LV remodeling (I) are 
decreased to control levels 42 days following DOX removal.  Error bars = standard deviation. *p<0.05, 
**p<0.01, +p<0.001 compared to littermate controls.  #p<0.05 compared to double transgenic mice 42 
days on DOX. 
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Figure 3.8 Induction of caFGFR1 results in transient ERK1/2 activation and sustained 
downregulation of Akt activation.  (A) Representative Western blots examining signaling pathways 
downstream of the FGF receptor.  Note that most pathways examined, as well as p38 and Stat5 (not 
shown), showed considerable variability.  (B) Densitometric analysis of multiple independent Western 
blots demonstrated a transient, but insignificant, 2-fold increase in ERK1/2 activation, and a sustained 
decrease in Akt activation.  DTG (shown): n0d=5, n1d=3, n7d=8, n21d=6; controls (not shown): n0d=2, n1d=2, 
n7d=4, n21d=3.  Error bars = standard deviation. *p<0.05. 
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Figure 3.9 Double transgenic mice have significantly decreased troponin I phosphorylation and 
Serca2 expression.  (A) Representative Western blots depicting no changes in the expression of 
phosphorylated protein kinase A (P-PKA) and decreased expression of phosphorylated troponin I (P-TnI) 
and Serca2a2.  -tubulin was used as a loading control.  (B) Densitometric quantitation of p-TnI/t-TnI and 
Serca2a2, demonstrating a significant decrease in both by seven days of caFGFR1 induction.  Fold 
change is versus corresponding time-matched littermate controls (not shown). DTG (shown): n0d=5, 
n1d=8, n7d=8, n21d=6, n168d=2; controls (not shown): n0d=2, n1d=5, n7d=4, n21d=3, n168d=2.  Error bars = 
standard deviation. *p<0.05, **p<0.01. 
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Figure 3.10 Ventricular myocytes from double transgenic mice have impaired relaxation and 
enhanced contraction.  Double transgenic (DTG) and littermate controls were induced for 24-48 hours 
with DOX chow, and then unloaded cell shortening was assessed in freshly isolated ventricular myocytes.  
(A) Representative tracings illustrating the contractile differences between cardiomyocytes from DTG and 
control hearts.  (B) DTG myocytes were significantly shorter at both systole and diastole, (C) with an 
overall increase in fractional shortening (n=4 mice, 17 myocytes total for both control and DTG).  (D)  
Addition of BDM, an inhibitor of actin-myosin interactions, caused significant relaxation of both DTG and 
control myocytes, (E) and resulted in a greater change in sarcomere length in DTG myocytes (n=3 mice 
each, 19 control myocytes, 23 DTG myocytes).  .  Error bars=standard deviation.  **p<0.01, +p<0.001 
DTG vs. littermate controls; # p<0.05 vs. respective baseline measurements.  
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Table 3.1 Hemodynamic analysis of double transgenic and littermate control mice following 24 
hours on DOX. Note absence of differences in all parameters except end systolic and end diastolic 
volumes (ESV, EDV). bpm, beats per minute; MAP, mean arterial pressue; ESP, end systolic pressure; 
EDP, end diastolic pressure; EF, ejection fraction; dP/dt, change in pressure over change in time. 
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Table 3.2 Hemodynamic analysis of double transgenic and littermate control ice following 42 days 
on DOX.  Note the significant increases in end systolic pressure (ESP) and tau (Glantz).  bpm, beats per 
minute; EDP, end diastolic pressure; ESV, end systolic volume; EDV, end diastolic volume; EF, ejection 
fraction; dP/dt, change in pressure over change in time. 
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Table 3.3 Blockade of FGFR tyrosine kinase partially ameliorates LV hypertrophy development in 
caFGFR1-expressing mice. Mice were injected with PD173074 (FGFR tyrosine kinase inhibitor), U0126 
(MEK1/2 inhibitor), Wortmannin (PI3K inhibitor), or Cyclosporine A (calcineurin inhibitor) for one week 
prior to addition of DOX chow.  Drugs were continued throughout one week of transgene induction.  DTG 
mice injected with the FGFR tyrosine kinase inhibitor, PD173074 (DTG PD17) had significantly lower LV 
mass index compared to DTG mice without drug.  However, PD173074 did not reduce the peak outflow 
velocity (LV POV).  Inhibition of other pathways downstream of the FGF receptor had little effect on 
phenotype development.  PD17=PD173074, an FGFR tyrosine kinase inhibitor; U0126=MEK1/2 inhibitor; 
Wort=Wortmannin, a PI3K inhibitor; CsA=Cyclosporine A, a calcineurin inhibitor; DTG=double transgenic, 
Ctl=single transgenic control. * p<0.05 compared to DTG 7d; # p<0.05 compared to baseline;  p<0.05 
compared to respective single transgenic controls (ctl).   
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Table 3.4 Blockade of beta-adrenergic and angiotensin receptors lessens phenotype development 
in caFGFR1-expressing mice.  Mice were given propranolol or losartan in their drinking water one week 
before the start of DOX chow.  Drugs were continued throughout one week transgene induction.  Double 
transgenic mice given propranolol (DTG Pro) or losartan (DTG Los) had significantly lower LV mass index 
(LVMI) compared to one-week induced double transgenic mice without drug (DTG 7d).  Additionally, 
propranolol (but not losartan) was able to significantly decrease the LV peak outflow velocity (LV POV) in 
DOX-induced double transgenic mice, although outflow velocity remained significantly elevated compared 
to baseline.  Pro=propranolol, Los=losartan, DTG=double transgenic, Ctl=single transgenic control.  
*p<0.05 compared to DTG 7d; # p<0.05 compared to baseline;  p<0.05 compared to respective single 
transgenic controls (ctl).   
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Chapter 4 
Conclusions and Future Directions 
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 Cardiovascular disease is a major public health problem that costs billions of dollars every year.  
Current strategies in heart failure treatment are directed at removing the causative factor (as in 
hypertension) or managing symptoms when this is not possible (as in myocardial infarction or genetic 
cardiomyopathies).  One of the common components and key determinants of outcome in cardiovascular 
disease is myocardial remodeling, which results in changes in cardiac energetics and myocardial 
perfusion, in addition to the diastolic and systolic capacity of the heart [191].  This is an incredibly 
complex process that involves the interplay between different cellular populations in the hearts 
(endothelial, fibroblast, myocyte, inflammatory, vascular smooth muscle, etc.) as well as a variety of 
different signaling pathways.  Additionally, the heart possesses the capacity for more beneficial 
remodeling to occur, as this is required during normal postnatal growth, as well as to accommodate the 
increased cardiovascular demands during pregnancy and exercise training.  The balance between 
physiological remodeling and pathological remodeling is poorly understood, but clearly, it would be 
beneficial to inhibit maladaptive and promote favorable pathways.  To do so, however, requires a much 
greater understanding of the signaling molecules and receptors that govern cardiac growth. 
FGF2-knockout studies have demonstrated the clear necessity for this ligand in ventricular 
remodeling following injury or pressure overload, while other studies have shown FGF1 and FGF9 may 
also be beneficial to the remodeling process  [31, 77, 85, 87-93, 97, 100, 107].  However, other FGF 
ligands that are involved in cardiovascular development are also expressed in the adult heart, and little is 
known regarding the roles they play during postnatal cardiac homeostasis, in addition to myocardial 
remodeling.  In addition, the cellular targets of FGF signaling have not been investigated.  The main goal 
of my thesis was to better characterize FGF signaling in the adult heart, with regard to how FGF ligand 
and receptor gene expression change in response to different physiological and pathological stimuli, as 
well as to gain a better understanding of how FGF signaling is regulated in the adult heart.  Several 
pathways activated downstream of the FGF receptor have been clearly implicated in different aspects of 
ventricular remodeling, with proteins like SOS1, SHP2, and RAS involved in the development of 
hypertrophic cardiomyopathy, ERK1/2 and PKC involved in secondary pathological hypertrophy, and 
PI3K/Akt associated with physiological hypertrophy.  Therefore, the FGF signaling pathway represents a 
potentially important therapeutic target for modulating ventricular remodeling in the adult heart. 
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Using an inducible cardiac-specific FGF9-overexpressing mouse model, Kory Lavine, a previous 
graduate student in our lab, implicated FGF9 in the pathogenesis of fibrosis and progression to heart 
failure.  Given the involvement of FGF2 in the myocardial remodeling process, I hypothesized that FGF9 
expression, as well as the expression of other FGF ligands and receptors, may be elevated in different 
types of pathological remodeling.  What I discovered was that expression of Fgf16, significantly more so 
than Fgf9, was very tightly and consistently regulated following different pathological and physiological 
stimuli.  In all cases of pathological insults examined (aortic constriction, MI, AngII), Fgf16 expression was 
significantly repressed, while it showed slight but significant upregulation in physiological hypertrophy 
models.  This was in contrast to Fgfr1 and Fgf2 which were significantly upregulated following MI and 
significantly downregulated in exercise-induced hypertrophy (Table 2.1). 
These findings suggest several possibilities for the regulation of FGF signaling (presented in 
Figure 2.10), which are the focus of ongoing studies in our lab.  Recent evidence suggests that FGF16 
can oppose the growth-promoting action of FGF2 [39], which provides a potential model to explain the 
mirrored expression pattern of Fgf2 and Fgf16 under pathological and physiological conditions.  I 
hypothesize that FGF16 levels must decrease in order for FGF2 to mediate myocardial remodeling 
following injury.  It is also possible that the balance between these two ligands is critical for physiological 
remodeling to occur.  Thus, it will be important to examine the response to exercise-induced hypertrophy 
in FGF2-knockout and –overexpressing mice, as well as FGF16-knockout mice.  Additionally, I believe 
the creation of an FGF16-transgenic or inducible FGF16 mouse line (similar to our TRE-FGF9 mouse 
line) will be useful for these future experiments.  Further in vitro studies will also be helpful to determine a 
more precise mechanism through which FGF16 inhibits FGF2-mediated myocyte growth. 
The gene expression studies also suggested that a means of regulating the responsiveness to 
FGF signals is through regulation of receptor expression.  Following MI, both Fgfr1 and Fgfr2 are 
significantly upregulated in both the infarcted and noninfarcted myocardium, implicating them as key 
receptors for the FGF2-mediated remodeling process, and providing an explanation for a lack of 
spontaneous hypertrophy development in FGF2-overexpressing mouse models.  Further support for this 
model of regulation comes from studies presented in Chapter 3, in which I observed little to no expression 
of FGFR1 protein in the uninjured adult heart (Figure 3.1B), despite the presence of moderate levels of 
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Fgfr1 cDNA seen in quantitative RT-PCR studies.  I thus hypothesize that under homeostatic conditions, 
FGFR1 is rapidly degraded (perhaps downstream of FGF16-mediated signaling), but is stabilized in the 
membrane following pathological insult.  Rapid receptor desensitization is one of the key methods by 
which G-protein coupled receptor signaling is regulated [192], so it is possible that a similar mechanism 
can be extended to receptor tyrosine kinases. 
Another model that would explain the lack of a baseline hypertrophy phenotype in FGF2-
overexpressing hearts is that FGF receptors are uncoupled from their downstream signaling pathways 
under homeostatic conditions.  To test this hypothesis, Kory Lavine created a cardiomyocyte-specific, 
doxycycline-inducible constitutively-active FGFR1 mouse line, and I anticipated that induction of this 
receptor would not result in cardiomyocyte hypertrophy unless the heart were injured.  However, I 
observed a remarkable increase in cardiac contractility with low baseline levels of caFGFR1 expression, 
with the rapid development of hypertrophic cardiomyopathy within one week of transgene induction.  This 
phenotype was present in 100% of mice expressing caFGFR1.  Despite the continual progression of 
hypertrophy, caFGFR1-expressing hearts maintained their systolic function and none of the mice 
experienced heart failure or sudden cardiac death, even in response to forced exercise.  Intriguingly, 
upon mechanistic evaluation, I did not observe activation of any of the classical FGF-activated pathways, 
including ERK1/2, Akt, Stat3, Stat5, p38, JNK, or PLC, which was consistent with finding from a Ras-
induced HCM model [178].  Meanwhile, I noted a significant decrease in troponin I phosphorylation and 
expression of Serca2, suggesting the possibility that myofilament calcium sensitivity or intracellular 
calcium handling were altered.  In vitro experiments utilizing freshly isolated ventricular myocytes from 
acutely-induced mice (24-48 hours on DOX chow) demonstrated impaired sarcomere relaxation in 
addition to enhanced fractional shortening.  Partial rescue of the phenotype was achieved by inhibiting 
myosin-actin cross bridge formation, but not through chelation of intracellular calcium.  These findings 
strongly suggested that caFGFR1 is capable of rapidly altering myocyte contractile properties, at least 
partly through direct effects on myofilament physiology, and not via the increased availability of cytosolic 
calcium.  These studies have suggested the possibility of a novel downstream pathway capable of 
altering sarcomere biomechanics, but how or why this particular pathway is activated in caFGFR1-
expressing myocytes is currently unclear and warrants further investigation.  Future studies examining 
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skinned myofilaments are necessary to investigate mechanical properties more closely, in addition to 
calcium imaging studies in isolated myocytes to confirm the absence of calcium handling defects.  
Furthermore, expression and activation of protein phosphatases 1 and 2a should be examined, as these 
enzymes could provide a link between the FGF receptor and altered myocardial contractility. 
It is most likely that FGF signaling is regulated by a combination of all of these mechanisms, 
which allow the signals, the cellular targets, and the responses to be fine-tuned to the particular stimulus.  
It is clear that we have only begun to scratch the surface of cardiac FGF signaling, as many significant 
questions remain. In what cells are the various ligands and receptors expressed and in what cells are 
they necessary and/or sufficient to induce remodeling in the adult heart?  In order to appropriately target 
treatments and understand which remodeling effects are cell autonomous or non-autonomous, receptor 
loss-of-function studies must be performed.  Other than cardiomyocyte-specific double conditional 
receptor knockout discussed in Chapter 2, I established several other DCKO lines to ablate Fgfr1/2 
expression from endothelial and epicardial cells that are currently being used in our lab to assess the 
relative contribution(s) of FGF signaling to the different cell types during periods of normal physiological 
cardiac growth, physiological hypertrophy, and following MI.   
When does the cardiomyocyte response to FGF signaling switch from proliferation to 
hypercontractility and hypertrophy, and what FGF ligands are capable of reproducing the 
hypercontractility observed in caFGFR1-expressing mice?  The doxycycline-inducible FGF9 and 
caFGFR1 mouse lines can be utilized to investigate myocardial responsiveness to FGF signals at 
different postnatal time points.  In addition, I created a new doxycycline-inducible FGF2 mouse line that 
can be used to assess the effects of acutely increasing FGF2 expression at different time points and in in 
different cells. 
Finally, what factors determine which downstream signaling pathway(s) gets activated?  How can 
we direct FGF signaling towards the more beneficial PI3K-Akt pathway and away from the maladaptive 
ERK1/2 or PKC pathways?  Is there a way to translate the caFGFR1-mediated hypercontractility into a 
viable treatment alternative for patients with systolic dysfunction?  Answering all of these questions will be 
essential in order to harness the full potential of the FGF signaling pathway and implement it in such a 
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way to therapeutically guide the tissue response to injury towards physiological, rather than the 
pathological remodeling. 
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Chapter 5 
Materials and Methods  
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Mouse models. TRE-caFGFR1 mice were generated by Kory Lavine by subcloning a cDNA 
fragment encoding FGFR31C(R248C)-cmyc into pTRE2 (Invitrogen). The resultant pTRE2-
FGFR31C(R248C) vector was linearized and injected into FVB blastocysts. 8 founder lines were obtained 
and 4 were screened by crossing the founder to αMHC-rtTA transgenic mice, feeding double transgenic 
offspring doxycycline chow (Research Diets), and assaying for transgene expression by western blot. 
Western blotting was performed using antibodies against the c-myc epitope and β-tubulin (see more 
detailed description of WB below).  All mice were maintained on a mixed background, primarily 
C57/Bl6/129.   
MHC-rtTA, TRE-FGF9 mice were fed doxycycline-containing chow (DOX, Research Diets) for 
20 days to induce transgene expression.  Mice were then analyzed utilized echocardiography, and 
postmortem analysis described below.  MHC-rtTA, TRE-caFGFR1 mice were fed DOX chow for varying 
lengths of time (from 24 hours up to ten months) and analyzed using techniques described below. 
To inactivate FGF receptor signaling in cardiomyocytes, MHC-CreER, FGFR1
f/f
, FGFR2
f/f
 DCKO 
mice were injected with 40mg/kg tamoxifen (Sigma).  Briefly, 40 mg of tamoxifen was added to 400 L of 
100% ethanol and sonicated until dissolved.  3.6 mL of sunflower seed oil (Sigma) was then added and 
the solution was sonicated again until it was homogenous, for a final tamoxifen concentration of 
10mg/mL.  For an average mouse of 25g, 100 L was injected intraperitoneally using a 25-gauge needle. 
TRE-FGF2 mice were generated by subcloning a cDNA fragment encoding human Fgf2 into the 
pTRE2-FGF9/EGFP plasmid (Figure 5.1).  Fgf9 was excised from the plasmid utilizing SacII and EcoRI 
restriction enzymes, according to the protocol from New England Biolabs (NEB, “Optimizing Restriction 
Endonuclear Reactions”: 500 ng plasmid, 0.5 L of each restriction enzyme, 2.5L 10x buffer, 0.25L 
100x BSA, and water up to 25L; 37C water bath for 1 hour).  The digest was separated on a 0.7% 
agarose gel, and the ~4 kb fragment was excised and purified utilizing the Qiagen gel extraction kit.  A 
linker segment was created to add an additional EcoRI restriction site into the plasmid.  5’-
AATTCCGTCGACTTGC-3’ and 5’-AAGTCGACGG-3’ oligomers were purchased from Integrated DNA 
Technologies and reconstituted as directed.  To anneal the oligomers into the linker segment, 100L of 
each oligomer were mixed together and heated to 94C, then cooled to room temperature.  The linker was 
ligated into the pTRE2 plasmid utilizing the standard NEB protocol for “DNA ligation with T4 DNA Ligase,” 
98 
 
and then transformed into DH5 bacteria.  Briefly, 5 L of the ligation mix was added to 100L bacteria, 
placed on ice for 30 minutes, then at 42C for 90 seconds, then back on ice for 2 minutes.  300L of LB 
was added and samples were placed in the 37C shaker for 1 hour, after which they were plated in agar 
dishes containing ampicillin overnight in the 37C shaker.  Several colonies were selected the following 
morning using sterile loops and placed in 15-mL round bottom tubes with 6 mL of LB and 6L of 
ampicillin.  Minipreps were incubated in the 37C shaker overnight, and plasmids were isolated the 
following day utilizing the Qiagen Miniprep kit. 
A human FGF2 plasmid was generously provided by Marja Hurle; FGF2 was excised utilizing an 
EcoRI digest and 960 bp segment was purified as described for the pTRE2 plasmid.  The pTRE2-linker 
plasmid was opened using EcoRI and gel purified.  Ligation of the p-TRE2-linker and FGF2 fragments 
was achieved utilizing a 1:10 vector:insert ratio.  Transformation and purification of plasmids were 
performed as described above.  Plasmids were digested with SalI (which was introduced in the linker and 
would make only one cut) and then screened for proper size (5.12 kb).  Appropriately-sized bands were 
excised, re-ligated and maxi-prepped utilizing a Qiagen Maxiprep kit.  FGF2 transgene (3.4 kb) was 
excised for injection into FVB blastocysts utilizing AatII and DrdI.  Nine founder lines were obtained and 
are currently being screened by Southern blot for GFP to determine the most stable line. 
Echocardiography. Non-invasive ultrasound examination of the cardiovascular system was 
performed using a Vevo 2100 Ultrasound System (VisualSonics Inc, Toronto, Ontario, Canada) according 
to the following procedures. First, mice were lightly anesthetized with an intraperitoneal injection of 2% 
Avertin (tribromoethanol, 0.005 ml/g). One fifth of the initial dose was given as a maintenance dose at 
regular intervals depending on the level of anesthesia. Low-dose Avertin was used because it does not 
have significant negative inotropic or chronotropic effect. Hair was removed from the anterior chest with a 
combination of shaving and chemical hair remover, and the animals were placed on a warming pad in a 
left lateral decubitus position. Ultrasound coupling gel was applied to the chest. Examination of cardiac 
structure and function under these near-physiologic condition was obtained with hand-held manipulation 
of the ultrasound transducer. Care was taken to maintain adequate contact while avoiding excessive 
pressure on the chest. Complete two-dimensional, M-mode, and Doppler ultrasound examination was 
performed from multiple views. After completion of the imaging studies, mice were kept warm and allowed 
99 
 
to recover until returned to their cage. Digitally acquired images were analyzed off-line on a computer 
workstation running Vevo 2100 analysis software. [Methods and echocardiography performed by Dr. 
Attila Kovacs in the Washington University Mouse Cardiovascular Phenotyping Core.  Analysis performed 
by Sarah Cilvik.] 
Cardiac Surgery. Eight- to 12-week-old mice were subjected to LAD ligation (MI) or ascending 
aortic banding, as previously described [154, 193, 194].  Surgeries were performed by Carla Weinheimer 
in the Washington University Mouse Cardiovascular Phenotyping Core. 
Hemodynamic Analysis. Adult mice were anesthetized with thiopental sodium 60 mg/kg 
administered i.p. This anesthesia produces a near physiologic heart rate of 500 beats/min while still 
allowing for a surgical plane of anesthesia. The mice were intubated and ventilated with a Harvard 
ventilator set at 200-400 μl. The bilateral carotid arteries were identified in the region of the trachea and 
the right carotid was cannulated with a 1.4 french high fidelity micromonometer pressure-volume catheter 
(SciSense Advantage System, London, Ontario, Canada).  The catheter was advanced retrogradely 
through the aortic valve into the left ventricle to assess pressure volume loops. Continuous aortic 
pressures, LV systolic and diastolic pressures, the derivative of LV pressure (dP/dT), and tau was 
recorded and analyzed with Scisense analysis software.  Pressure-volume loops were analyzed. before, 
during, and after an occlusion of the IVC to assess load-independent measurements of myocardial 
contractility. [Written by Attila Kovacs and performed by Carla Weinheimer and Carrie Giersach in the 
Washington University Mouse Cardiovascular Phenotyping Core.] 
Exercise tolerance. To determine if chronic induction of caFGFR1 and the resulting concentric 
hypertrophy would result in impair performance during forced exercise, adult mice were fed DOX chow for 
six months and then subjected to an acute treadmill stress test, where their exercise tolerance was 
measured by the length of time they were able to run unassisted (time to failure).  Exercise tests were 
carried out using a state-of-the-art Exer4-OxyMax motorized treadmill (Columbus Instruments, Columbus, 
Ohio).  Electrified bars delivered a very mild stimulus when a mouse failed to keep pace with the belt.  For 
this experiment, mice began running at 10 meters/min, and the speed was increased by 3 meters/min 
every 3 minutes.  Time to failure was reached when a mouse remained on the electrified bar for >5 
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seconds.  [Protocol adapted from Carla Weinheimer and run in collaboration with Carrie Giersach in 
Washington University Mouse Cardiovascular Phenotyping Core.] 
Inhibitor studies.  Eight- to 12-week-old MHC-rtTA, TRE-caFGFR1 mice were treated with one 
of the following drugs, starting one week prior to addition of DOX chow and continuing throughout the one 
week of transgene induction: Losartan (600mg/L in drinking water, Sigma #61188), propranolol (500mg/L 
in drinking water, Sigma #P0884), diltiazem (450mg/L in drinking water, Sigma #D2521), Cyclosporine A 
(15mg/kg twice daily subcutaneous injections, Sigma #30024), Wortmannin (1mg/kg/d IP, Sigma 
#W1628), U0126 (1mg/kg IP every 3 days, Calbiochem #662005), or PD173074 (1mg/kg/d IP, Pfizer), 
according to published studies [177, 190, 195-198]. 
Myocyte Isolation, cell contractility, and sarcomere length measurements. Ventricular 
myocytes from acutely-induced (24-48 hours following doxycycline treatment) control or double 
transgenic (caFGFR1-expressing) mice were isolated using a method described previously [199].  
Following isolation, the ventricular myocyte suspension was washed 3 times in Wittenberg Isolation 
medium containing 50mg/ml BSA, 12.5mg/ml Taurine with increasing concentrations of CaCl2 (150uM, 
400uM, and 900uM).  The cells were then washed with Tyrode’s solution containing (in mM) NaCl, 137; 
KCl, 5.4; NaH2PO4, 0.16; glucose, 10; CaCl2, 1.0; MgCl2, 0.5; HEPES, 5.0; NaHCO3, 3.0; pH 7.3–7.4.  
Freshly isolated myocytes were transferred to a recording chamber mounted on the stage of a Nikon 
Diaphot inverted microscope and perfused at 60ml/hour with normal Tyrode’s solution. The cells were 
allowed to settle for 5 minutes and were subsequently paced at 5-10V at 0.5 Hz for 5 minutes before 
recording.  All experiments were performed at room temperature. Video images of individual myocyte 
contractions were acquired and analyzed using a Myocam camera (IonOptix).  To assess the relaxation 
of diastolic sarcomere length, cells were loaded with 100uM BAPTA-AM (Sigma) for 1 hour prior to 
recording or treated with Tyrode’s solution containing 40mM 2, 3-butanedione monoxime (BDM) (Sigma). 
[Methods written and performed by Keita Uchida in the lab of Colin Nichols.] 
Gross pathology and histological analysis. At study endpoints, mice were fully anesthetized 
with an intraperitonieal injection of 2.5% Avertin (0.015 mL/g) and total body weight was measured.  
Hearts were removed, rinsed briefly in PBS, and then placed into a solution of PBS saturated with 
potassium chloride to arrest hearts in diastole.  Both outflow tract and atria were carefully dissected away, 
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and biventricular weight was measured.  Normalized heart size was determined by calculating the ratio of 
biventricular weight (mg) to overall mouse weight (g; heart weight: body weight ratio).  The apical third of 
the heart was removed and flash frozen in liquid nitrogen for protein or RNA analysis, while the remaining 
heart tissue was fixed in 10% neutral buffered formalin for 24-48 hours at room temperature.  Samples 
were then dehydrated in 70% ethanol, embedded in paraffin, cut in 5 µm sections, and stained with H&E.  
Fibrosis was detected on sections using a Picrosirius red stain kit (24901, Polysciences, Inc., Warrington, 
PA) with Weigert’s iron hematolxylin counterstaining (HT1079, Sigma-Aldrich, St. Louis, MO).   
Fluorescein-tagged wheat germ agglutinin (FITC-WGA, L4895, Sigma-Aldrich, St. Louis, MO) 
was used to label all cell membranes, thus illuminating areas of increased interstitial cells and also 
making quantitation of cardiomyocyte cross-sectional area possible.  Sections were dewaxed using 
xylenes, rehydrated through an ethanol series to water, rinsed in PBS, and then stained with WGA-FITC 
(1:100) for one hour at room temperature.  Finally, sections were rinsed and mounted in Vectashield Hard 
Set with DAPI (H-1500, Vector Laboratories, Burlingame, CA), and imaged using a Zeiss Apotome 
Microscopy system.  Five to ten images showing cardiomyocytes in cross section were taken from 
different regions of the ventricular wall in each sample, and mean cardiomyocyte cross sectional area 
was determined by tracing (using ImageJ software) the membrane of at least 300 cardiomyocytes per 
sample. 
For analysis of Cre activation in MHC-CreER DCKO R26R hearts, staining for -galatctosidase 
was performed.  Hearts were placed in Mirsky’s fixative (National Diagnostics, HS-102) overnight at room 
temperature, and then rinsed the following day with PBS and placed in 30% sucrose (in PBS) overnight at 
4C.  Hearts were then mounted in OCT and frozen at -80C.  Twelve-m sections were cut using a 
cryostat.  Slides were allowed to warm to room temperature for 30 minutes and then placed in a humidity 
chamber and stained with LacZ stain: 950 L LacZ wash buffer (498 mL 1x PBS, 1 mL 1M MgCl2, 1mL 
10% NP40), 0.25mM potassium ferrous cyanide, 0.25mM potassium ferric cyanide, and 50L of 2% X-
gal stock (in DMF).  Slides were protected from light and placed at 37C for 1-2 hours, room temperature 
for 8-10 hours, or 4C overnight, and checked periodically for development of stain.  Once complete 
staining was achieved, slides were rinsed in PBS (5 minutes x 3), followed by tap water (5 minutes), and 
then counterstained with nuclear fast red for 2-5 minutes.  Finally, slides were rinsed in tap water (5 
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minutes x 2), followed by 100% ethanol (2 minutes x 2), followed by xylenes (5 minutes x 2), and then 
mounted with cytoseal. 
Protein extraction and Western blotting. Protein was extracted from flash frozen apical pieces 
of the heart using RIPA buffer (50mM Tris pH7.4, 150mM NaCl, 1mM EDTA, 1% NP-40, 0.1% SDS, 1% 
sodium deoxycholate, 1% Triton x-100) with freshly added 2% Protease Inhibitor Cocktail (P8340, Sigma-
Aldrich) and Phosphatase Inhibitor Cocktail I and II (P2850 and P5726, Sigma-Aldrich).  Protein 
concentration was determined utilizing a Pierce BCA assay kit (23225, Thermo Scientific, Rockford, IL).  
Total protein (60 µg) was separated on NuPAGE Novex 4-12% Bis-Tris Midi gels (WG1401, Invitrogen, 
Grand Island, NY) and transferred to PVDF membranes (iBlot Gel Transfer Stacks PVDF Regular, 
IB4010, Invitrogen).  Membranes were blocked for one hour at room temperature with gentle shaking in 
TBST (50mM Tris, pH7.4, 150mM NaCl, 0.1% Tween20) containing 5% nonfat milk, and then probed with 
the antibodies listed in Table 5.1 overnight at 4ºC.  After three rinses in TBST, membranes were 
incubated for one hour at room temperature in horseradish peroxidase-linked secondary antibodies, as 
described in Table 5.1, in TBST with 5% nonfat milk, rinsed again in TBST, and developed using 
SuperSignal West Femto Maximum Sensitivity Substrate (34096, Thermo Scientific). 
The membrane was then stripped utilizing multiple washes of boiled 100 mM glycine and TBST 
wash buffer at room temperature (glycine reprobing protocol using the iBlot dry blotting system, 
Invitrogen) and sequentially reprobed with additional antibodies.  Protein bands were quantified by 
densitometry, and protein loading normalized to β-tubulin.  Phospho-ERK1/2 and phospho-Akt were 
normalized to total-ERK1/2 and total-Akt protein levels, and then scaled relative to controls, where control 
samples were set at a value of 1. 
RNA isolation, cDNA synthesis, and quantitative RT-PCR. RNA was extracted from flash 
frozen apical pieces of the heart using a Qiagen RNeasy Mini kit (protocol from Appedix C in 3
rd
 edition 
RNeasy Mini Handbook, 74104, Qiagen, Valencia, CA), with on-column DNA digest.  RNA concentration 
was determined utilizing a Nanodrop spectrophotometer.  cDNA was made using the BioRad iScript 
Reverse Transcription Supermix for RT-qPCR kit (170-8841, BioRad, Hercules, CA).  Quantitative RT-
PCR was performed on an Applied Biosystems (ABI) 7500 machine using ABI Taqman® Fast Advaned 
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Master Mix (ABI #4444557) and Taqman® gene expression assays listed in Table 5.2 (ABI).  All samples 
were normalized to Hprt and then scaled relative to controls using the standard ddCt method. 
Statistical analysis. In all figures, error bars represent standard deviation, unless otherwise 
noted.  Statistical analysis was carried out using a standard student T-test, with a p<0.05 considered 
significant.  Individual outliers were determined using Grubbs’ test. 
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Figure 5.1 pTRE2-FGF2/EGFP plasmid. 
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Table 5.1 Primary and secondary antibodies utilized for Western blotting. 
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Table 5.2 ABI Taqman® Gene Expression Assays for quantitative RT-PCR analysis. 
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